

## Contents

HEPATITIS B.....	5
HEPATITIS C.....	8
HIV.....	29
HAE.....	40
IPF/PAH.....	41
NASH.....	44
RHEUMATOLOGY.....	47
RARE DISEASES.....	53
ARTICLES.....	59

CANCER

American Society of Hematology (ASH) 2019

Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome

Authors: Janna Radtchenko, Daniel Lyons, Yvonne Barnes, Scott Milligan, and Edward Drea
DOI: 10.1182/blood-2019-124319
Blood 134(Supplement\_1): 2203-2203

Abstract accepted at 61st American Society of Hematology, 2019
December 7-10; Orlando, Florida




HEMOPHILIA

Haemophilia the Journal of the World Federation of Hemophilia

Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A

Authors: Young, G, Callaghan, MU, Balasa, V, et al.
DOI: https://doi.org/10.1111/hae.14826

Published in Haemophilia the Journal of the World Federation of Hemophilia. August 8, 2023



American Thrombosis & Hemostasis Network (ATHN) 2022

Effects of Pharmacokinetic Assessment on Clinical Outcomes for Patients with Moderate to Severe Hemophilia A

Authors: Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo


Poster presented at: ATHN Data Summit, 2022 Oct 19-21; London, England, U.K.



International Society on Thrombosis and Hemostasis (ISTH) 2022

**Effects of Pharmacokinetic Assessment on FVIII Consumption and Estimated Costs for Patients with Moderate to Severe Hemophilia A**

**Authors:** Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo  
[International Society on Thrombosis and Haemostasis 2022; 2022 July 9-13: Abstract PBO689](#)



Poster presented at: 30th Congress of the International Society on Thrombosis and Haemostasis, 2022 July 9-13; London, England, U.K.

**Effects of Pharmacokinetic Assessment on Clinical Outcomes for Patients with Moderate to Severe Hemophilia A**

**Authors:** Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo  
[International Society on Thrombosis and Haemostasis 2022; 2022 July 9-13: Abstract PBO688](#)



Poster presented at: 30th Congress of the International Society on Thrombosis and Haemostasis, 2022 July 9-13; London, England, U.K.

**Real-World Study of Rurioctocog Alfa Pegol and Emicizumab in US Clinical Practice Among Patients with Hemophilia A**

**Authors:** Shawn X. Sun, Andrew Frick, Vinod Balasa, and Jonathan C. Roberts  
 DOI: [10.1080/17474086.2022.2112171](https://doi.org/10.1080/17474086.2022.2112171)




Published in: Expert Review of Hematology- Online Access: August 2022

**American Society of Hematology (ASH) 2021**

**A Retrospective Descriptive Study on the Effectiveness and Usage of Emicizumab and Antihemophilic Factor (recombinant), Fc Fusion Protein in Patients with Hemophilia A in the US**

**Authors:** Alex Cockerham, Amanda Wilson, Andrew Frick, and Pronabesh Dasmahapatra  
 DOI: [10.1182/blood-2021-148325](https://doi.org/10.1182/blood-2021-148325)



Poster presented at: 63rd American Society of Hematology, 2021 December 11-14; Atlanta, Georgia

**Academy of Managed Care Pharmacy (AMCP) 2021 VIRTUAL**

**A Retrospective Study of Rurioctocog Alfa Pegol and Emicizumab Wastage, Consumption, and Costs in US Clinical Practice Among Patients with Hemophilia A**

**Authors:** Shawn X. Sun, Andrew Frick

DOI: [10.18553/jmcp.2021.27.4-a.s1](https://doi.org/10.18553/jmcp.2021.27.4-a.s1)

Journal of Managed Care + Specialty Pharmacy 2021 Apr; 27(4-a Suppl): S47-D17

Poster presented at: AMCP Managed Care and Specialty Pharmacy Annual Meeting, 2021 Apr 12-16 and published in Journal of Managed Care + Specialty Pharmacy




**European Association for Haemophilia and Allied Disorders (EAHAD) 2021 - VIRTUAL**

**A Retrospective Study of the Impact of Switching Patients with Haemophilia A to Rurioctocog Alfa Pegol or Emicizumab in US Practice**

**Authors:** Shawn X. Sun, Andrew Frick

DOI: [10.1111/hae.14236](https://doi.org/10.1111/hae.14236): ABS039

ePoster presented at: European Association for Haemophilia and Allied Disorders and published in the Wiley Online Library online; 2021 February 3-5



**International Society on Thrombosis and Haemostasis (ISTH) 2020 - VIRTUAL**

**Real-World Outcomes before and after Switching from Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in the United States**

**Authors:** Shawn X. Sun and Scott Milligan  
[Res Pract Thromb Haemost. 2020; 4 \(Suppl 1\).](https://doi.org/10.1111/rpth.12501)

ePoster presented at: Virtual Congress and published online only as an addendum supplement to the ISTH open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH), 2020 July 12-14



**A Retrospective, Observational Study using Specialty Pharmacy Data of Rurioctocog Alfa Pegol Use in the United States**

**Authors:** Louis Aledort, MD, Scott Milligan, PhD, Maureen Watt, MSc, and Jason Booth, MPH

DOI: [10.18553/jmcp.2020.26.4.492](https://doi.org/10.18553/jmcp.2020.26.4.492)

J Manag Care Spec Pharam, 2020 Apr;26(4):492-503.

Published in: Journal of Managed Care & Specialty Pharmacy (JMCP): April 2020



**American Society of Hematology (ASH) 2019**

**Real-world, Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data**

**Authors:** Maureen Watt, Scott Milligan  
 DOI: [10.1182/blood-2019-124101](https://doi.org/10.1182/blood-2019-124101)  
*Blood* (2019) 134(Supplement\_1): 2411

Poster presented at: 61<sup>st</sup> American Society of Hematology, 2019 December 7-10; Orlando, Florida



**International Society on Thrombosis and Haemostasis (ISTH) 2019**

**A Retrospective, Observational Study using Specialty Pharmacy data of Rurioctocog Alfa Pegol Use in the United States**

**Authors:** Maureen Watt and Scott Milligan  
 DOI: [10.1002/rth2.12229](https://doi.org/10.1002/rth2.12229)  
*Res Pract Thromb Haemost.* 2019; 3 (Suppl 1): PB0702

Poster presented at: International Society on Thrombosis and Haemostasis Meeting, 2019 July 6-10; Melbourne, Australia




**Academy of Managed Care Pharmacy (AMCP) 2018**

**Retrospective, Observational Study of BAX 855 in Clinical Practice in the United States**

**Authors:** J. Booth, M. Watt, S. Milligan, and L. Aledort.  
 DOI: [10.18553/jmcp.2018.24.4-a.s1](https://doi.org/10.18553/jmcp.2018.24.4-a.s1)  
*AMCP Managed Care & Specialty Pharmacy* 2018; 24, No.4-a: D7

Poster presented at: AMCP Managed Care and Specialty Pharmacy Annual Meeting, 2018 Apr 23-26; Boston, MA



**HEPATITIS B**

**First-Line Therapies for Hepatitis B in the United States: A 3-year Prospective and Multicenter Real-World Study after Approval of Tenofovir Alafenamide**

**Authors:** Calvin Q. Pan, Nezam H. Afdhal, Victor Ankoma-Sey, Ho Bae, Michael P. Curry, Douglas Dieterich, Lynn Frazier, Andrew Frick, Hie-Won Hann, W. Ray Kim, Paul Kwo, Scott Milligan, Myron J. Tong, and K. Rajender Reddy  
 DOI: [10.1002/hep4.1964](https://doi.org/10.1002/hep4.1964)

Published in: *Hepatology Communications*: Online April 21, 2022



**The European Association for the Study of the Liver (EASL) 2020 – VIRTUAL**

**Longer-Term Experience with Tenofovir Alafenamide (TAF) in HBV-Infected Patients; Changes in eGFR, FIB4, ALT, and DNA Suppression**

**Authors:** Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #SAT457](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29




**Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice**

**Authors:** Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #SAT448](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29



**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020 – VIRTUAL**

**Hepatitis B Treatment Patterns in US Clinical Care Following Tenofovir Alafenamide (TAF) Approval**

**Authors:** Dr. Michael P. Curry, Dr. Ho S Bae, Dr. Douglas T Dieterich, Dr. Victor AnkomaSey, Dr. K Rajender Reddy, MD, FAASLD, Prof. Calvin Q. Pan, Dr. Hie-Won L Hann, Dr. Myron J Tong, Dr. W. Ray Kim, MD, MBA, FAASLD9, Dr. Paul Y Kwo, MD, Mrs. Lynn Frazier, Ms. Kimmi Cox, Dr. Scott Milligan, and Nezam H Afdhal

[DOI: 10.1016/j.jval.2020.04.484](#)

Poster presented at: VIRTUAL ISPOR 2020 May 15-20; Published in Value in Health and ISPOR site



**The American Association for the Study of Liver Diseases (AASLD) 2019**

**Differential Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice**

**Authors:** Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal

[Journal of Hepatology. October 2019; 70 \(suppl 1\): Abstract #486](#)

Poster presented at: The Liver Meeting. 70th Annual Meeting of the American Association for the Study of Liver Diseases; 2019 Nov 8-12; Boston, MA



**Longer-Term Experience with Tenofovir Alafenamide (TAF) in HBV-Infected Patients; Changes in eGFR, FIB-4, ALT, and HBV DNA Suppression**

**Authors:** K. Rajender Reddy, Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal  
[Journal of Hepatology. October 2019; 70 \(suppl 1\): Abstract #487](#)



Poster presented at: The Liver Meeting. 70th Annual Meeting of the American Association for the Study of Liver Diseases; 2019 Nov 8-12; Boston, MA

**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019**

**Clinical Practice Experience with Tenofovir Alafenamide (TAF) for Treatment of Hepatitis B in the US**

**Authors:** Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Janna Radtchenko, and Nezam Afdhal  
[DOI: 10.1016/j.jval.2019.04.883](#)



Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA

**The European Association for the Study of the Liver (EASL) 2019**

**Effectiveness and Safety with Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice**

**Authors:** Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz, and Nezam Afdhal  
[DOI: 10.1016/S0618-8278\(19\)30912-0](#)



Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria

**Asian Pacific Association for the Study of the Liver (APASL) 2019**

**Effectiveness and Safety with Tenofovir Alafenamide (TAF) for Hepatitis B in Patients of Asian Race in US Clinical Practice**

**Authors:** Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz, and Nezam Afdhal.  
[DOI: 10.1007/s12072-019-09936-5: Abstract#627](#)

Effectiveness and Safety with tenofovir alafenamide (TAF) for Hepatitis B in Patients of Asian race in US clinical practice  
 K. Rajender Reddy, MD  
 Philadelphia USA

Oral presented at: APASL 2019. 28th Annual Conference of the Asian Pacific Association for the Study of Liver (APASL); 2019 Feb 20-24; Manila, Philippines

The American Association for the Study of Liver Diseases (AASLD) 2018

**Treatment of Hepatitis B in the US: Real-World Evidence from the TRIO Network**

**Authors:** Ho Bae, Michael Curry, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, and Nezam Afdhal.

[Journal of Hepatology. October 2018; 68 \(suppl 1\): Abstract #445](#)

Poster presented at: The Liver Meeting. 69th Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC




**Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice: Real-World Evidence from the TRIO Network**

**Authors:** Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, and Nezam Afdhal

[Journal of Hepatology. October 2018; 68 \(suppl 1\): Abstract #423](#)

Poster presented at: The Liver Meeting. 69th Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC



HEPATITIS C

The European Association for the Study of the Liver (EASL) 2022

**Changing HCV Patient Profiles: Insights From a Large Multinational Real-World Sofosbuvir/Velpatasvir (SOF/VEL) Dataset**

**Authors:** A Mangia, S Fagioli, V Di Marco, S Shafran, M Khalili, S Milligan, G Papatheodoridis, D Ouzan, S Rosati, A Ramji, E Teti, M Garcia-Retortillo, F Andres, Perez Hernandez, A Wong, C Fraser, S Rodriguez-Tajes, E Jimenez Mutiloa, LE Morano Amado, J O'Loan, F Campanale, G Macedo, M Milella, C Brixko, M Buti, MF Guerra Veloz, R Ranieri, S Borgia, A Bascia, CM Fernandez Rodriguez, B Conway, V de Ledinghen, M Fenech, P Ryan, I Maida, A Martins, S Scherbakovsky, I Ntalla, C Hernandez, K Vanstraelen, and J Turnes

[The International Liver Congress 2022; 2022 June 22-26](#)

Poster presented at: The International Liver Congress 2022; 2022 June 22-26; London, United Kingdom



**Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders**

**Authors:** Heiner Wedemeyer, Vito Di Marco, Montserrat Garcia-Retortillo, Elisabetta Teti, Chris Fraser, Luis Enrique Morano Amado, Sergio Rodriguez-Tajes, Silvia Acosta-Lopez, Joss O’Loan, Michele Milella, Maria Buti, Maria Fernanda Guerra-Veloz, Alnoor Ramji, Mary Fenech, Alexandra Martins, Sergio M. Borgia, Kim Vanstraelen, Michael Mertens, Candido Hernandez, Ianna Ntalla, Heribert Ramroth, and Scott Milligan  
 DOI: [10.3390/v14112493](https://doi.org/10.3390/v14112493)

Published in: Viruses- Online Access: November 2022



**Global Hepatitis Summit (GHS) 2020/2021**

**Multinational Evaluation of Comedication and Drug-drug Interactions in Hepatitis C Patients Treated with Pangenotypic Direct-acting Antivirals**

**Authors:** Stefano Fagioli, Scott Milligan, Juan Turnés, Alessandra Mangia, Andreas Hintz, Nicole Wick, Antoni Sicras, Luca DegliEsposti, Frank Tacke, Ramón Morillo, Gema Alvarez Nieto, Gero Niess, Stacey Scherbakovsky, Marinela Méndez, Hsin-Jung Lin, Kim Vanstraelen, Candido Hernandez, and Tim Umland


Poster presented at: Global Hepatitis Summit 2020/2021- The 17<sup>th</sup> International Symposium on Viral Hepatitis and Liver Disease (ISVHLD); 2021 June 18-20



**Is the Age of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large Multinational Real-world Dataset**

**Authors:** Juan Turnés, Alessandra Mangia, Mandana Khalili, Scott Milligan, Stefano Fagioli, Vito Di Marco, George Papatheodoridis, Stanislas Pol, Silvia Rosati, Alnoor Ramji, Elisabetta Teti, Lisa Barrett, Montserrat Garcia-Retortillo, Francisco Pérez Hernández, Alexander Wong, Chris Fraser, Sergio Rodriguez-Tajes, Elena Jiménez Mutilo, Luis Morano, Joss O’Loan, Francesca Campanale, Guilherme Macedo, Michele Milella, Christian Brixko, Maria Buti, Maria Fernanda Guerra Veloz, Roberto Ranieri, Sergio Borgia, Annalisa Bascià, Conrado M Fernandez-Rodriguez, Brian Conway, Victor De Lédighen, Mary Fenech, Pablo Ryan, Ivana Maida, Alexandra Martins, Ioanna Ntalla, Hsin-Jung Lin, Candido Hernandez, Kim Vanstraelen, Stacey Scherbakovsky, and Stephen D Shafran  
[Global Hepatitis Summit 2020/2021; 2021 June 18-20](https://doi.org/10.3390/v14112493)


Poster presented at: Global Hepatitis Summit 2020/2021- The 17<sup>th</sup> International Symposium on Viral Hepatitis and Liver Disease (ISVHLD); 2021 June 18-20



**Is the Gender of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large Multinational Real-world Dataset**

**Authors:** Alessandra Mangia, Silvia Rosati, Lisa Barrett, Elisabetta Teti, Montserrat Garcia Retortillo, Elena Jiménez Mutilo, Francesca Campanale, Maria Buti, Maria Fernanda Guerra Veloz, Annalisa Bascià, Mary Fenech, Ivana Maida, Alexandra Martins, Juan Turnés, Scott Milligan, Stefano Fagioli, Vito Di Marco, Stephen D Shafran, George Papatheodoridis, Denis Ouzan, Alnoor Ramji, Francisco Pérez Hernández, Alexander Wong, Chris Fraser, Sergio Rodríguez-Tajes, Luis Morano, Joss O’Loan, Guilherme Macedo, Michele Milella, Christian Brixko, Roberto Ranieri, Sergio Borgia, Conrado M Fernandez-Rodriguez, Brian Conway, Victor De Lédighen, Pablo Ryan, Stacey Scherbakovsky, Hsin-Jung Lin, Kim Vanstraelen, Ioanna Ntalla, Candido Hernandez, and Mandana Khalili

[Global Hepatitis Summit 2020/2021; 2021 June 18-20](#)



Poster presented at: Global Hepatitis Summit 2020/2021- The 17<sup>th</sup> International Symposium on Viral Hepatitis and Liver Disease (ISVHLD); 2021 June 18-20

**Spanish Association for the Study of the Liver (AEEH) 2021- VIRTUAL**

**Eficacia de sofosbuvir/velpatasvir (SOF/VEL) en pacientes con infección crónica por VHC y trastornos psiquiátricos: resultados en práctica clínica real en 6 países**

**Authors:** García-Retortillo M, Milligan S, Barrett L, Teti E, Wedemeyer H, Fraser C, Morano L, Rodríguez-Tajes S, Acosta-López S, O’Loan J, Milella M, Buti M, Guerra Veloz MF, Ramji A, Fernández-Rodríguez CM, Martins Figueiredo L, Fenech M, Jiménez Mutilo E, Macedo G, Maida I, Ryan P, Campanale F, Bascià A, Conway B, Ranieri R, Borgia S, De Lédighen V, Mangia A, Mertens M, Vanstraelen K, Ntalla I, Hernández-López C, and Di Marco V

[Gastroenterol Hepatol. 2021; 44 Supl Congr 2: 32-118: Abstract #64](#)



ePoster presented at: The 46<sup>th</sup> Annual Spanish Association For the Study of the Liver; 2021 June 14-16

**Prevalence of Drug-Drug Interactions with Pangenotypic Direct-Acting Antivirals for Hepatitis C and Real-World Care Management in the United States: A Retrospective Observational Study**

**Authors:** Michael P Curry, MD, Steven L Flamm, MD, Scott Milligan, PhD, Naoky Tsai, MD, Nicole Wick, AS, Zobair Younossi, MD, and Nezam H Afdhal, MD

DOI: [10.18553/jmcp.2021.20550](https://doi.org/10.18553/jmcp.2021.20550)

Published in: Journal of Managed Care + Specialty Pharmacy: June, 2021



**The American Association for the Study of Liver Diseases (AASLD) 2020 – VIRTUAL**

**Effectiveness of Sofosbuvir/Velpatasvir (SOF/VEL) in Patients with Chronic HCV Infection and Mental Health Disorders: Real-World Care Management from 8 Countries**

**Authors:** Milligan S, Barrett L, Teti E, Garcia-Retortillo M, Wedemeyer H, Fraser C, Morano L, Rodriguez-Tajes S, Acosta-Lopez S, O’Loan J, Milella M, Buti M, Guerra Veloz MF, Ramji A, Fernandez-Rodriguez CM, Martins Figueiredo L, Fenech M, Jimenez Mutiloa E, Macedo G, Maida I, Ryan P, Campanale F, Bascia A, Conway B, Ranieri R, Borgia S, De Ledinghen V, Mangia A, Mertens M, Vanstraelen K, Ntalla I, Hernandez-Lopez C, and Di Marco V

[Journal of Hepatology. November 2020; 72 \(suppl 1\): Abstract #905](#)




Poster presented at: The Liver Meeting Digital Experience: American Association for the Study of Liver Diseases; 2020 Nov 13-16

**The European Association for the Study of the Liver (EASL) 2020 - VIRTUAL**

**Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C; Understanding the Populations at Risk and Real-World Care Management**

**Authors:** Michael Curry, Naoky Tsai, Bruce Bacon, Steven Flamm, Zobair Younossi, Scott Milligan, Nicole Wick, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #THU435](#)




Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29

**Pangenotypic Therapies Glecaprevir-Pibrentasvir (G-P) and Sofosbuvir-Velpatasvir Voxilaprevir (S-V-V) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C**

**Authors:** Steven Flamm, Naoky Tsai, Bruce Bacon, Michael Curry, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal

[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #SAT387](#)



Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29

**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020 – VIRTUAL**

**Real-World Effectiveness of Hepatitis C Virus (HCV) Treatment with Direct-Acting Antivirals (DAA) in Populations with Fatty Liver/Non-Alcoholic Steatohepatitis (FL/NASH), Decompensated Cirrhosis (DCC), Hepatocellular Carcinoma (HCC), and/or Post Liver Transplant (PTX)**

**Authors:** Zobair Younossi, Bruce Bacon, Michael Curry, Steven Flamm, Andrew Frick, Scott Milligan, Janna Radtchenko, Naoky Tsai, and Nezam Afdhal

[DOI: 10.1016/j.jval.2020.04.478](https://doi.org/10.1016/j.jval.2020.04.478)



Poster presented at: Virtual ISPOR 2020 May 15-20; Published in Value in Health and ISPOR site

**Real-World Effectiveness of Direct-Acting Antivirals (DAA) in Young Adult (18-25) and Elderly (80+) Populations with Hepatitis C (HCV)**

**Authors:** Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Andrew Frick, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal  
 DOI: [10.1016/j.jval.2020.04.483](https://doi.org/10.1016/j.jval.2020.04.483)

Poster presented at: Virtual ISPOR 2020 May 15-20; Published in Value in Health and ISPOR site



**Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Simple, Effective HCV Treatment: Analysis of 5552 Patients from 12 Cohorts**

**Authors:** Alessandra Mangia, Scott Milligan, Mandana Khalili, Stefano Faggioli, Stephen D. Shafran, Fabrice Carrat, Denis Ouzan, George Papatheodoridis, Alnoor Ramji, Sergio M. Borgia, Heiner Wedemeyer, Ruggero Losappio, Francisco Perez-Hernandez, Nicole Wick, Robert S. Brown Jr, Pietro Lampertico, Karen Doucette, Ioanna Ntalla, Heribert Ramroth, Michael Mertens, Kim Vanstraelen, and Juan Turnes  
 DOI: [10.1111/liv.14537](https://doi.org/10.1111/liv.14537)

Published in: Liver International: May 25, 2020



**Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection**

**Authors:** Steven L. Flamm, Jens Kort, Steven E. Marx, John Strezewski, Douglas E. Dylla, Bruce Bacon, Michael P. Curry, Naoky Tsai, and Nicole Wick  
 DOI: [10.1007/s12325-020-01301-5](https://doi.org/10.1007/s12325-020-01301-5)

Published in: Advances in Therapy: April 11, 2020



**Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV/HCV**

**Authors:** Sonia Vibhakar Patel, Dushyantha T. Jayaweera†, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax, Jason Gillman, Karam Mounzer, Richard A. Elion, and Gregory D. Huhn  
 DOI: [10.1371/journal.pone.0228847](https://doi.org/10.1371/journal.pone.0228847)

Published in: PLOS ONE: February 13, 2020




**Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Patients with Chronic HCV Infection: A Meta-Analysis**

**Authors:** Pietro Lampertico, Jose A. Carrion, Michael Curry, Juan Turnes, Markus Cornberg, Francesco Negro, Ashley Brown, Marcello Persico, Nicole Wick, Ariel Porcalla, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Yu, Heiner Wedemeyer

[DOI: 10.1016/j.jhep.2020.01.025](https://doi.org/10.1016/j.jhep.2020.01.025)

Published in: Journal of Hepatology: February 12, 2020




**The American Association for the Study of Liver Diseases (AASLD) 2019**

**Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management**

**Authors:** Dr. Michael P. Curry, Prof. Naoky C Tsai, Dr. Bruce R Bacon, Dr. Steven L Flamm, Prof. Zobair M Younossi, MD, MPH, FAASLD, Dr. Scott Milligan, Mrs. Nicole Wick, and Nezam H Afdhal

Poster presented at: The Liver Meeting. 70th Annual Meeting of the American Association for the Study of Liver Diseases; 2019 Nov 8-12; Boston, MA



**Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C**

**Authors:** Steven L Flamm, Naoky C Tsai, Bruce R Bacon, Michael P. Curry, Scott Milligan, Nicole Wick, Zobair M Younossi, and Nezam H Afdhal

Poster presented at: The Liver Meeting. 70th Annual Meeting of the American Association for the Study of Liver Diseases; 2019 Nov 8-12; Boston, MA



**The European AIDS Clinical Society (EACS) 2019**

**Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies**

**Authors:** R. Elion, K. Althoff, J. Eron, J. Gillman, R. Haubrich, G. Huhn, S. Milligan, A. Mills, K. Mounzer, G. Moyle, J. Radtchenko, S. Santiago, P. Sax, and D. Jayaweera

[The 17th European AIDS Clinical Society; 2019 Nov 6-9: PE19](#)

Poster presented at: The 17th European AIDS Conference; 2019 Nov 6-9; Basel, Switzerland




**American College of Gastroenterology (ACG) 2019**

**Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Hepatitis C Virus Infection: A Meta-Analysis**

**Authors:** Markus Cornberg, Francesco Negro, Pietro Lampertico, Juan Turnes, Michael P. Curry, Ashley Brown, Heiner Wedemeyer, Jose A Carrion, Nicole Wick, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Yu, and Marcello Persico

Poster presented at: American College of Gastroenterology 2019 Conference; 2019 Oct 25-29; San Antonio, Texas



**Canadian Liver Meeting 2019**

**Global Real World Evidence of Sofosbuvir/Velpatasvir as a Simple, Effective Regimen for the Treatment of Chronic Hepatitis C: Integrated Analysis of 12 clinical Practice Cohorts**

**Authors:** Dr. Alessandra Mangia, Dr. Scott Milligan, Prof. Mandana Khalili, Prof. Stefano Fagioli, Dr. Stephen D. Shafran, Prof. Fabrice Carrat, Prof. Denis Ouzan, Prof. George Papatheodoridis, Dr. Sergio M Borgia, Prof. Heiner Wedemeyer, Valeria Piazzolla, Francisco Perez, Ms. Nicole Wick, Dr. Dawn Fishbein, Prof. Pietro Lampertico, Dr. Karen Doucette, Dr. Michael Mertens, Dr. Kim Vanstaelen, Dr. A. Anna Kumaraswamy, Dr. Juan Turnes

Oral presented at: Canadian Liver Meeting 2019 Conference; 2019 May 24-26; Montreal, Canada




**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019**

**Access to HCV Cure Under Medicaid Programs in the United States**

**Authors:** Zobair Younossi, Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Janna Radtchenko, Naoky Tsai, and Nezam Afdhal

Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA



**The European Association for the Study of the Liver (EASL) 2019**

**Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US**

**Authors:** Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer, and Rick Elion  
[2019 Apr 10-Online Access](#)

Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



**Clinical Practice Experience with Pangenotypic Therapies Glecaprevir-Pibrentasvir and Sofosbuvir-Velpatasvir; Data from the Trio Network**

**Authors:** Michael Curry, Bruce Bacon, Steven L Flamm, Nicole Wick, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



**Effectiveness of the Salvage Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Chronic Hepatitis C; Clinical Practice Experience from the Trio Network**

**Authors:** Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



**Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir (G/P) for Treatment Naïve, Noncirrhotic Patients with HIV Infection in the TRIO Network**

**Authors:** Michael P. Curry, Jens Kort, Steven E. Marx, John Strezewski, Nicole Wick, Steven L. Flamm, Bruce Bacon, and Naoky Tsai  
Published in: GastroHep Wiley Online Library: November 23, 2019



**Changing Demographics Among Populations - Prescribed HCV Treatment, 2013-2017**

**Authors:** Naoky Tsai, MD, Bruce Bacon, MD, Michael Curry, MD, Steven L. Flamm MD, Scott Milligan, PhD, Nicole Wick, AS, Zobair Younossi, MD, and Nezam Afdhal, MD  
[American Journal of Managed Care](#)

Published in: American Journal of Managed Care (AJMC): July 12, 2019




**The American Association for the Study of Liver Diseases (AASLD) 2018**

**Change in Demographics of Direct-Acting Antiviral (DAA)-Prescribed HCV Patients from 2013 to 2018: Data from 19,994 Patients in the TRIO Network**

**Authors:** Naoky Tsai, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Zobair Younossi and Nezam Afdhal.


Poster presented at: The Liver Meeting. 69th Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC



**Effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) for Treatment Naïve, Non-Cirrhotic Patients with HCV Infection in the TRIO Health Network**

**Authors:** Steven L. Flamm, Jens Kort, Steve Marx, John Strezewski, Bruce Bacon, Michael P. Curry, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: The Liver Meeting. 69<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC



**Preferences and Outcomes in Clinical Practice with Glecaprevir/Pibrentasvir (GLE-PIB), Ledipasvir/Sofosbuvir (LDV-SOF), and Sofosbuvir/Velpatasvir (SOFVEL): Data from the TRIO Network**

**Authors:** Michael Curry, Bruce Bacon, Steven L. Flamm, Michael Marks, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster presented at: The Liver Meeting. 69<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC



**Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Care of Chronic Hepatitis C Patients: Clinical Practice Experience from the TRIO Network**

**Authors:** Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: The Liver Meeting. 69<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC



**Disparities in Accessing HCV Care Under Medicaid Programs Across the US: Experience from the TRIO Network**

**Authors:** Zobair Younossi, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Naoky Tsai, and Nezam Afdhal

Oral presentation at: The Liver Meeting. 69<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases; 2018 Nov 9-13; Washington, DC

Disparities in Accessing HCV Care under Medicaid Programs Across the US; Experience from the TRIO Network

Zobair Younossi<sup>1</sup>, Bruce Bacon<sup>2</sup>, Michael Curry<sup>3</sup>, Steven L. Flamm<sup>4</sup>, Scott Milligan<sup>5</sup>, Nicole Wick<sup>6</sup>, Naoky Tsai<sup>7</sup>, and Nezam Afdhal<sup>8</sup>


<sup>1</sup>Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, <sup>2</sup>St. Louis University School of Medicine, <sup>3</sup>Beth Israel Deaconess Medical Center, <sup>4</sup>Northwestern University Feinberg School of Medicine, <sup>5</sup>Trio Health Analytics, and <sup>6</sup>University of Hawaii

**Global Hepatitis Summit (GHS) 2018**

**Realized Durations of Direct-Acting Antivirals (DAAs) in Care of HCV in US Clinical Practice: Data from the Trio Network**

**Authors:** Michael Curry, Bruce Bacon, Steven Flamm, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal.

Poster presented at: Global Hepatitis Summit. 2018 June 14-17; Toronto, Canada




Digestive Disease Week (DDW) 2018

**Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load <6mm IU/ml: Analyses of Real-World Data from the TRIO Network**

**Authors:** Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington, DC



**Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network**

**Authors:** Bruce Bacon, Michael Curry, Steven Flamm, John Straub, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC




**Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network**

**Authors:** Dushwantha Jayaweera, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

[DOI: 10.1016/S0016-5085\(18\)33931-3](https://doi.org/10.1016/S0016-5085(18)33931-3)


Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC



**Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network**

**Authors:** Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC



**Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network**

**Authors:** Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal.


Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC



**Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network**

**Authors:** Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal.

Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC



**Behavioral and Clinical Factors and Direct Acting Antiviral (DAA) Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network**

**Authors:** Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, and Karam Mounzer  
 DOI: [10.1016/S0016-5085\(18\)33670-9](https://doi.org/10.1016/S0016-5085(18)33670-9)


Oral presented at: Digestive Disease Week. 2018 June 2-5; Washington DC



**The European Association for the Study of the Liver (EASL) 2018**

**Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the TRIO Network**


**Authors:** Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal  
 Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



**Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network**

**Authors:** Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion  
 DOI: [10.1016/S0168-8278\(18\)30723-2](https://doi.org/10.1016/S0168-8278(18)30723-2)

Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



**Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network**

**Authors:** Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi, and Nezam Afdhal


Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



**Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network**

**Authors:** Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal


Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



**Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network**

**Authors:** Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster presented at: The International Liver Congress. 53rd Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



**The Impact of Individual Patient Data in a Network Meta Analysis: An Investigation Into Parameter Estimation and Model Selection**

**Authors:** Joy Leahy, Aisling O’Leary, Nezam Afdhal, Emma Gray, Scott Milligan, Malte H. Wehmeyer, and Cathal Walsh

Published in: Research Synthesis Methods: June 20, 2018



**Real-world Use of Elbasvir-Grazoprevir in Patients with Chronic Hepatitis C: Retrospective Analyses from the TRIO Network**

**Authors:** Flamm, SL, Bacon B, Cury MP, Milligan S, Nwankwo CU, Tsai N, Younossi Z, and Afdhal N

Published in: Alimentary Pharmacology & Therapeutics (AP&T): April 17, 2018



The American Association for the Study of Liver Diseases (AASLD)

**Real-World Patterns of Therapy Utilization and Outcomes in 8,049 HCV Patients: Data from the TRIO Network**

**Authors:** Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal


Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



**Drivers of Therapy Choice in Genotype 1 HCV: Analyses of Real-World Data from the TRIO Network**

**Authors:** M. Curry, B. Bacon, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi. and N. Afdhal

Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



**HCV Treatment Failure in the Era of Direct-Acting Antivirals (DAAs): Analyses of Real-World Data from the TRIO Network**

**Authors:** Bruce Bacon, Steven L. Flamm, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



**Cure Denied and Cure Delayed in Chronic Hepatitis C; Monitoring Non-Start Rates and Increased Time to Start Using Real-World Data from the TRIO Network**

**Authors:** Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, and Nezam Afdhal

Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



**Impact of Treatment Duration and Ribavirin (RBV) Addition on Real-World Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Select Patient Subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective Data Analyses from the TRIO Network**

**Authors:** C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC



**Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Treatment Naïve (TN) Genotype 1a (GT1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A Resistance-Associated Substitutions (RASs)**

**Authors:** C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal.

Poster presented at: The Liver Meeting. 68th Annual Meeting of the American Association for the Study of Liver Diseases; 2017 Oct 20-24; Washington, DC




**Digestive Disease Week (DDW) 2017**

**Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network**

**Authors:** S.L. Flamm, B. Bacon, M. Curry, D. Dieterich, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster presented at: Digestive Disease Week. 2017 May 6-9; Chicago, IL



**Sofosbuvir/ Velpatasvir Compared to Existing Standards of Care in GT2-6 HCV**

**Authors:** Michael Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal


Oral presented at: Digestive Disease Week. 2017 May 6-9; Chicago, IL



**Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network**

**Authors:** N. Tsai, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, Z. Younossi, and N. Afdhal

Poster presented at: Digestive Disease Week. 2017 May 6-9; Chicago, IL



**Access to HCV Care for 31,154 Patients in the United States Real-World Experience from the TRIO Network**

**Authors:** Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, and Nezam Afdhal

Poster presented at: Digestive Disease Week. 2017 May 6-9; Chicago, IL



**The European Association for the Study of the Liver (EASL) 2017**

**Sofosbuvir/ Velpatasvir Compared to Existing Standards of Care in GT2-6 HCV**

**Authors:** Michael Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Oral presented at: The International Liver Congress. 52nd Annual Meeting of the European Association for the Study of the Liver; 2017 Apr 13-17; Amsterdam, Netherlands



**Real-World Treatment Utilization and Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network**

**Authors:** S.L. Flamm, B. Bacon, M. Curry, D. Dieterich, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal


Poster presented at: The International Liver Congress. 52nd Annual Meeting of the European Association for the Study of the Liver; 2017 Apr 13-17; Amsterdam, Netherlands



**Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network**

**Authors:** N. Tsai, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, Z. Younossi, and N. Afdhal


Poster presented at: The International Liver Congress. 52nd Annual Meeting of the European Association for the Study of the Liver; 2017 Apr 13-17; Amsterdam, Netherlands



**Elbasvir/Grazoprevir Effectiveness in Patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-World Experience from the TRIO Network**

**Authors:** Z. Younossi, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, C. Nwankwo, and N. Afdhal


Poster presented at: The International Liver Congress. 52nd Annual Meeting of the European Association for the Study of the Liver; 2017 Apr 13-17; Amsterdam, Netherlands



**Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network**

**Authors:** B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, C. Nwankwo, N. Tsai, Z. Younossi, and N. Afdhal

Poster presented at: The International Liver Congress. 52nd Annual Meeting of the European Association for the Study of the Liver; 2017 Apr 13-17; Amsterdam, Netherlands




The American Association for the Study of Liver Diseases (AASLD) 2016

**Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network**

**Authors:** Kevin Korenblat, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Kris V. Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal


Poster presented at: The Liver Meeting. 67th Annual Meeting of the American Association for the Study of Liver Diseases; 2016 Nov 11-15; Boston, MA



**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2016**

**Effectiveness of 8 or 12 week LDV/SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network**

**Authors:** Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi  
 Poster presented at: ISPOR 2016. 21st Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2016 May 21-25; Washington DC



**Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network**

**Authors:** Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi  
 Poster presented at: ISPOR 2016. 21st Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2016 May 21-25; Washington DC




**Digestive Disease Week (DDW) 2016**

**Ledipasvir/Sofosbuvir +/- Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network**

**Authors:** Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal


Poster presented at: Digestive Disease Week. 2016 May 21-24; San Diego, CA



**Access to Therapy in Era of DAA Regimens: Real-World Experience from the TRIO Network**

**Authors:** Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal

Poster presented at: Digestive Disease Week. 2016 May 21-24; San Diego, CA



**Failure with All-oral DAA Regimens: Real-World Experience from the Trio Network**

**Authors:** Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster presented at: Digestive Disease Week. 2016 May 21-24; San Diego, CA




**International Liver Transplantation Society (ILTS) 2016**

**Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network**

**Authors:** Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster presented at: ILTS 2016. 22nd Annual Congress of the International Liver Transplantation Society; 2016 May 4-7; Seoul, South Korea




**The European Association for the Study of the Liver (EASL) 2016**

**Ledipasvir/Sofosbuvir +/- Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network**

**Authors:** Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal


Poster presented at: The International Liver Congress. 51st Annual Meeting of the European Association for the Study of the Liver; 2016 Apr 13-17; Barcelona, Spain



**Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network**

**Authors:** Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal


Poster presented at: The International Liver Congress. 51st Annual Meeting of the European Association for the Study of the Liver; 2016 Apr 13-17; Barcelona, Spain



**No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real-World Data from 2,034 Genotype 1 Patients in the TRIO Network**

**Authors:** Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster presented at: The International Liver Congress. 51st Annual Meeting of the European Association for the Study of the Liver; 2016 Apr 13-17; Barcelona, Spain




**Asian Pacific Association for the Study of the Liver (APASL) 2016**

**Evaluation of Efficacy of Ledipasvir/Sofosbuvir for 12 weeks in a Real-Life Population of Genotype 1a and 1b HCV Patients: Data from the TRIO Network**

**Authors:** Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster presented at: APASL 2016. 25th Annual Conference of the Asian Pacific Association for the Study of Liver (APASL); 2016 Feb 20-24; Tokyo, Japan



**Real-world Effectiveness for 12 Weeks of Ledipasvir-Sofosbuvir for Genotype 1 Hepatitis C: The TRIO Health Study**

**Authors:** E. B. Tapper, B. R. Bacon, M. P. Curry, D. T. Dieterich, S. L. Flamm, L. E. Guest, K. V. Kowdley, Y. Lee, N. C. Tsai, Z. M. Younossi, and N. H. Afdhal

Published in: Journal of Viral Hepatitis: October 11, 2016



**Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes with Ledipasvir and Sofosbuvir in a Real-World Cohort Study**

**Authors:** Elliot B. Tapper, Bruce R. Bacon, Michael P. Curry, Douglas T. Dieterich, Steven L. Flamm, Lauren E. Guest, Kris V. Kowdley, Yoori Lee, Naoky C. Tsai, Zobair M. Younossi, and Nezam H. Afdhal

Published in: Hepatology: August 17, 2016



**Disparate Access to Treatment Regimens in Chronic Hepatitis C Patients: Data from the TRIO Network**

**Authors:** Z. M. Younossi, B. R. Bacon, D. T. Dieterich, S. L. Flamm, K. Kowdley, S. Milligan, N. Tsai, and A. Nezam

Published in: Journal of Viral Hepatitis: February 3, 2016




**The American Association for the Study of Liver Diseases (AASLD) 2015**

**Effectiveness of 8 or 12-week LDV-SOF in Treatment-Naïve Patients with NonCirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network**

**Authors:** Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster presented at: The Liver Meeting. 66th Annual Meeting of the American Association for the Study of Liver Diseases; 2015 Nov 13-17; San Francisco, CA



**Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network**

**Authors:** Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi


Poster presented at: The Liver Meeting. 66th Annual Meeting of the American Association for the Study of Liver Diseases; 2015 Nov 13-17; San Francisco, CA



**Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network**

**Authors:** Naoky Tsai, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Zobair Younossi, and Nezam Afdhal

Poster presented at: The Liver Meeting. 66th Annual Meeting of the American Association for the Study of Liver Diseases; 2015 Nov 13-17; San Francisco, CA




**Digestive Disease Week (DDW) 2015**

**Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network**

**Authors:** Kris Kowdley, Bruce Bacon, Douglas T. Dieterich, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi, and Steven L. Flamm

Poster presented at: Digestive Disease Week. 2015 May 16-19; Washington DC



**Evaluation of Access to Care in Patients Prescribed Sofosbuvir-containing Regimens; Data from the TRIO Network**

**Authors:** Zobair Younossi, Bruce Bacon, Douglas Dieterich, Steven Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, and Naoky Tsai


Poster presented at: Digestive Disease Week. 2015 May 16-19; Washington DC



**Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population**

**Authors:** Douglas Dieterich, Bruce Bacon, Steven Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Eric Lawitz


Poster presented at: Digestive Disease Week. 2015 May 16-19; Washington DC



**Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network**

**Authors:** Naoky Tsai, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, Douglas T. Dieterich

Poster presented at: Digestive Disease Week. 2015 May 16-19; Washington, DC




**The European Association for the Study of the Liver (EASL) 2015**

**Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population**

**Authors:** Douglas Dieterich, Bruce Bacon, Steven Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Eric Lawitz


Poster presented at: The International Liver Congress. 50th Annual Meeting of the European Association for the Study of the Liver; 2015 Apr 22-26; Vienna, Austria



**Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network**

**Authors:** Naoky Tsai, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Douglas T. Dieterich

Poster presented at: The International Liver Congress. 50th Annual Meeting of the European Association for the Study of the Liver; 2015 Apr 22-26; Vienna, Austria



**Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network**

**Authors:** Kris Kowdley, Bruce Bacon, Douglas T. Dieterich, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi, and Steven L. Flamm

Poster presented at: The International Liver Congress. 50th Annual Meeting of the European Association for the Study of the Liver; 2015 Apr 22-26; Vienna, Austria




**The American Association for the Study of Liver Diseases (AASLD) 2014**

**Evaluation of Sofosbuvir and OLYSIO-based Regimens in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population**

**Authors:** D Dieterich, B Bacon, S Flamm, K Kowdley, S Milligan, N Tsai, Z Younossi, E Lawitz


Oral presented at: The Liver Meeting. 65th Annual Meeting of the American Association for the Study of Liver Diseases; 2014 Nov 7-11; Boston, MA



**Efficacy of Sofosbuvir and Simeprevir-Based Regimens for HCV Treatment-Experienced GT1 Patients in a Real-Life Setting; Data from the TRIO Network**

**Authors:** Bruce Bacon, Douglas Dieterich, Steven Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Naoky Tsai


Poster presented at: The Liver Meeting. 65th Annual Meeting of the American Association for the Study of Liver Diseases; 2014 Nov 7-11; Boston, MA



**Evaluation of Efficacy of Sofosbuvir and Simeprevir-based Regimens in a Real-Life Population of HCV Patients with Cirrhosis; Data from the TRIO Network**

**Authors:** Steven Flamm, Bruce Bacon, Douglas Dieterich, Kris Kowdley, Eric Lawitz, Scott Milligan, Naoky Tsai, and Zobair Younossi

Poster presented at: The Liver Meeting. 65th Annual Meeting of the American Association for the Study of Liver Diseases; 2014 Nov 7-11; Boston, MA




HIV

Infectious Diseases Society of America (IDWeek) 2025

**Persistence and Virologic Outcomes of People with HIV (PWH) with Suboptimal Adherence on B/F/TAF or Dolutegravir-Based Single-Tablet Regimens**

**Authors:** Graeme Moyle, Joshua Gruber, Megan Dunbar, Janna Radtchenko, Isobel McEwen, Neia Prata Menezes, Travis Lim, Charles Walworth, Paul Sax, Steven Santiago, Hector Bolivar, Richard A. Elion


Poster presented at: IDWeek; 2025 October 19-22, Atlanta, GA



**PrEP Utilization Patterns and Indications in a Cohort of HIV-Negative Individuals**

**Authors:** Richard Elion, Kenneth Mayer, Rachel Scott, Aniruddha Hazra, Helen Koenig, Isobel McEwen, Chris Nguyen, Kristin Baker, Olayemi Oladapo, Yenyen Tran, Joshua Gruber, Brett Shannon, Janna Radchenko

Poster presented at: IDWeek; 2025 October 19-22, Atlanta, GA




European AIDS Conference (EACS) 2025

**Characteristics and Outcomes of People with HIV (PWH) Virally Suppressed on Complex Regimens**

**Authors:** Richard A. Elion, Keith Dunn, Janna Radtchenko, Bhumi Gandhi-Patel, Isobel McEwen, Seojin Park, Charles Walworth, Joseph J. Eron, Paul Benson, Karam Mounzer, Sebastian Ruhs, Moti Ramgopal, Steven Santiago

Poster presented at: 20<sup>th</sup> European AIDS Conference; October 15-18, 2025; Paris, France



AIDS Research and Therapy Journal

**Clinical outcomes on B/F/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort study**

**Authors:** Paul E. Sax, Janna Radtchenko, Megan Dunbar, Joshua Guber, Neia Prata Menezes, Karam Mounzer, Moti Ramgopal, Steven Santiago, Richard A. Elion  
Published in: AIDS Research and Therapy Journal: September 26, 2025

[Online access](#)

San et al. AIDS Research and Therapy (2025) 2:206  
https://doi.org/10.1186/s12981-025-00292-2

AIDS Research and Therapy

RESEARCH Open Access

Clinical outcomes on B/F/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort study

Paul E. Sax<sup>1</sup>, Janna Radtchenko<sup>2</sup>, Megan Dunbar<sup>3</sup>, Joshua Guber<sup>4</sup>, Neia Prata Menezes<sup>5</sup>, Karam Mounzer<sup>6</sup>, Moti Ramgopal<sup>7</sup>, Steven Santiago<sup>8</sup> and Richard A. Elion<sup>9</sup>\*

**Abstract**  
**Background** This retrospective observational study evaluated the clinical use and treatment outcomes in

AIDS Journal

**Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption**

**Authors:** Graeme Moyle, Joshua Gruber, Megan Dunbar, Janna Radtchenko, Andrew J. Frick, Andrea Marongiu, Paul E. Sax, Travis Lim, Steven Santiago, Paul Benson, Charles Walworth,

**Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption**

Graeme Moyle<sup>1</sup>, Joshua Gruber<sup>2</sup>, Megan Dunbar<sup>3</sup>, Janna Radtchenko<sup>4</sup>, Andrew J. Frick<sup>5</sup>, Andrea Marongiu<sup>6</sup>, Paul E. Sax<sup>7</sup>, Travis Lim<sup>8</sup>, Steven Santiago<sup>9</sup>, Paul Benson<sup>10</sup>, Charles Walworth<sup>11</sup> and Richard A. Elion<sup>12</sup>\*

**Objective** The objective of this study was to assess critical to maintaining HIV RNA suppression on antiretroviral (ARV) therapy. High genetic barrier regimens combined with three long-acting (LA) ARV agents may prevent assistance emergence and can be potentially started or restarted after unintentional treatment interruption.

**Methods** Data from the TRIO US HIV cohort were used to identify adult people with HIV initiating new ARV regimens from January 2021 to November 2023 and the prevalence of treatment interruption (TPI) defined as ≥90 days without documented ART. Virologic outcomes were assessed among those initiating or switching to B/F/TAF after treatment interruption.

**Results** Of 2779 people with HIV, 2163 experienced treatment interruption. Compared to individuals without treatment interruptions, those with treatment interruptions had higher proportions of women (34 vs. 19%), Black race (52 vs. 35%), substance use (44 vs. 39%), CD4<sup>+</sup> cell counts less than 200 cells/mm<sup>3</sup> (13 vs. 8%) and lower adherence with commercial insurance (46 vs. 42%) or virologic suppression at initiation (76 vs. 87%). Among 1379 who initiated or switched to B/F/TAF following treatment interruption,

Richard A. Elion

Published in: AIDS Journal: July 15, 2025


[Online access](#)

International AIDS Society (IAS) 2025

Predictors of Weight Gain Among People with HIV over 3-Year Period

**Authors:** R. Elion, J. Gruber, J. Radtchenko, M. Dunbar, N. Prata Menezes, J. Eron, C. Cohen, G. McComsey, P. Sax, G. Moyle

Oral presentation at: IAS: 2025 July 13-17: Kigali, Rwanda




1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025

Utilization and Effectiveness of Cabotegravir + Rilpivirine in People with HIV (PWH) with Viremia at Treatment Initiation

**Authors:** Richard A Elion, Andrew J Frick, Janna Radtchenko, Joseph J Eron, Steven Santiago, Karam Mounzer, Monica Mercon, Moti Ramgopal, Supriya Sarkar, Gayathri Sridhar, Vani Vannappagari, Jean van Wyk, Charles Walworth, Paul E Sax

Oral presentation at: LAAI; 2025 May 21-22; New Orleans, LA



American Conference for the Treatment of HIV (ACTHIV) 2025

Weight Concerns and Management in People with HIV (PWH) and without HIV (PWoH): A Qualitative Exploration of Healthcare Provider Experiences

**Authors:** Richard A. Elion, Joshua Gruber, Janna Radtchenko, Peter Slutzker, Neia Prata Menezes, Megan Dunbar, Steven Santiago, Cal Hoen, Paul Benson, Karam Mounzer, Moti Ramgopal, K Rivet Amico

Poster presented at: ACTHIV; 2025 May 1-3; Chicago, IL

[Online access](#)



25th International AIDS Conference 2024

**Characteristics and Outcomes of Virally Suppressed (VS) Treatment Experienced (VSTE) People with HIV (PWH)**

**Authors:** Gregory Huhn, Joshua Gruber, Isobel McEwen, Megan Dunbar, Janna Radtchenko, Charles Walworth, Joseph J. Eron, Karam Mounzer, Sebastian Ruhs, Moti Ramgopal, Steven Santiago, Richard A. Elion

Poster presented at: International AIDS Conference; 2024 July, 22-26; Munich, Germany

[Online access](#)



**Outcomes in People with HIV (PWH) Who Resume or Switch to B/F/TAF Following an Antiretroviral Treatment Interruption (ATI)**

**Authors:** Richard A. Elion, Joshua Gruber, Andrew Frick, Megan Dunbar, Janna Radtchenko, Paul E. Sax, Joseph J. Eron, Gregory Huhn, Anthony Mills, Paul Benson

Poster presented at: International AIDS Conference; 2024 July, 22-26; Munich, Germany

[Online access](#)




**Conference on Retroviruses and Opportunistic Infections (CROI) 2025**

**Characteristics and Treatment Outcomes of People with HIV Prescribed Fostemsavir in the Trio Cohort**

**Authors:** Moti Ramgopal, Cassidy Henegar, Andrew J. Frick, Janna Radtchenko, Isobel McEwen, Valeria Duran, Leigh Ragone, Michael Aboud, Steven Santiago, Karam Mounzer, Greg Huhn, Charles Walworth, Richard Elion, Vani Vannappagari

Poster presented at: CROI; 2025 March 9-12; San Francisco, CA


[Online access](#)



**Outcomes on Cabotegravir + Rilpivirine in Suppressed People with HIV (PWH) in TRIO Health US Cohort**

**Authors:** Paul E. Sax, Andrew J. Frick, Janna Radtchenko, Supriya Sarkar, Gayathi Sridhar, Leigh Ragone, Richard Elion, Joseph Eron, Steven Santiago, Karam Mounzer, Moti Ramgopal, Charles Walworth, Jean van Wyk, Vani Vannappagari

Poster presented at: CROI; 2025 March 9-12; San Francisco, CA




**Conference on Retroviruses and Opportunistic Infections (CROI) 2024**

**Weight Gain in People With HIV (PWH) vs People Without HIV (PWoH) Over a 3-Year Period**

**Authors:** Richard A. Elion, Joshua Gruber, Janna Radtchenko, Paul E. Sax, Megan Dunbar, Joseph J. Eron4, Cal Cohen, Gregory Huhn, Keri N. Althoff, Grace A. McComsey

Poster presented at: CROI; 2024 March, 3-6; Denver, CO

[Online access](#)




**Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Trio Health Cohort**

**Authors:** Kenneth Mayer, Carolyn Brown, Andrew Frick, Janna Radtchenko, Gayathri Sridhar, Leigh Ragone, Jean van Wyk, Anthony Mills, Steven Santiago, Richard Elion, Vani Vannappagari

Poster presented at: CROI; 2024 March, 3-6; Denver, CO

[Online access](#)




**Real-World Utilization of Cabotegravir + Rilpivirine in the US: Data From Trio Health Cohort**

**Authors:** Joseph J. Eron, Supriya Sarkar, Andrew Frick, Janna Radtchenko, Gayathri Sridhar, Leigh Ragone, Karam Mounzer, Steven Santiago, Jean van Wyk, Richard Elion, Vani Vannappagari

Poster presented at: CROI; 2024 March, 3-6; Denver, CO

[Online access](#)



**Infectious Diseases Society of America (IDWeek) 2023**

**Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in the United States: Trio Cohort Study**

**Authors:** Richard A. Elion, Andrew Frick, Janna Radtchenko, Supriya Sarkar, Gayathri Sridhar, Joseph J. Eron, Karam Mounzer, Jean Van Wyk, Vani Vannappagari

Poster presented at: IDWeek 2023 October 11-15; Boston, Massachusetts



**Exploring Antiretroviral Therapy (ART) Switch Decisions in Clinical Setting: Trio Health Mixed Methods Study**

**Authors:** Rick Elion, Megan Dunbar, K Rivet Amico, Joshua Gruber, Lauren Harrison, Grace McComsey, Peter Shalit, Janna Radtchenko

Poster presented at: IDWeek 2023 October 11-15; Boston, Massachusetts




**International AIDS Society Conference on HIV Science (IAS) 2023**

**Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in the United States: Trio Cohort Study**

**Authors:** R. Elion, S. Sarkar, J. Radtchenko, A. Frick, G. Sridhar, J.J. Eron, J.C. Gathe Jr., S. Santiago, J. Van Wyk, V. Vannappagari

[Online Access](#)

Poster presented at: 12th Annual International AIDS Society Conference on HIV Science July 23-26, 2023 Brisbane, Australia



**International Workshop on HIV and Hepatitis Observational Databases (IWHOD) 2023**

**Predictors of Switching to DTG/3TC vs B/F/TAF in US Clinical Practice**

**Authors:** Joshua Gruber, Megan Dunbar, Janna Radtchenko, Moshe Fridman, and Richard A. Elion

Poster presented at: 25<sup>th</sup> International Workshop on HIV and Hepatitis Observational Databases 2023. 2023 Mar 23-25



**Conference on Retroviruses and Opportunistic Infections (CROI) 2023**

**What Influences Switching to DTG/3TC VS B/F/TAF in Clinical Practice?**

**Authors:** Paul E. Sax, Joseph J. Eron, Janna Radtchenko, Megan Dunbar, Joshua Gruber, Moshe Fridman, Steven Santiago, Moti Ramgopal, Karam Mounzer, Gregory Huhn, and Richard A. Elion

[CROI Publications Database](#)

Poster presented at: CROI 2023. Annual Conference on Retroviruses and Opportunistic Infections; 2023 Feb 19-22



**HIV Glasgow 2022**

**Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among Prep-Naive (PN) Individuals After FTC/TAF Approval in the United States (US)**

**Authors:** Richard A. Elion, Joshua Gruber, Janna Radtchenko, Megan Dunbar, Kenneth H. Mayer, Gregory Huhn, Karam Mounzer, and Anthony Mills

[DOI: 10.1002/jia2.26009: P009](#)

Poster presented at: HIV Glasgow 2022. 2022 October 23-26; Published in Journal of the International AIDS Society and Glasgow



**Characteristics of Heavily Treatment Experienced (HTE) People with HIV (PWH) in US Clinical Practice**

**Authors:** Joseph J Eron, Megan S Dunbar, Janna Radtchenko, Joshua Gruber, Gregory Huhn, Grace A McComsey, Lauren Temme, and Richard A. Elion

[DOI: 10.1002/jia2.26009: P092](https://doi.org/10.1002/jia2.26009)

Poster presented at: HIV Glasgow 2022. 2022 October 23-26; Published in Journal of the International AIDS Society and Glasgow site



**Infectious Diseases Society of America (IDWeek) 2022**

**Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among PrEP-Naive (PN) Individuals After FTC/TAF Approval in the United States (US)**

**Authors:** Richard A. Elion, Joshua Gruber, Janna Radtchenko, Megan Dunbar, Kenneth H. Mayer, Gregory Huhn, Karam Mounzer, and Anthony Mills

[ID Week; 2022 October 19-23: Poster 2087](#)

Poster presented at: IDWeek 2022. 2022 October 19-23; Published in IDWeek site



**International AIDS Conference 2022**

**Utilization of Oral Pre-exposure Prophylaxis (PrEP) After FTC/TAF Approval in the United States**

**Authors:** Richard A. Elion, Joshua Gruber, Janna Radtchenko, Megan Dunbar, Kenneth H. Mayer, Gregory Huhn, and Karam Mounzer

[24<sup>th</sup> International AIDS Conference; 2022 July 29-August 2: EPC332](#)

Poster presented at: The 24<sup>th</sup> International AIDS Conference; 2022 July 29-August 2; Montreal, Canada, and virtually



**Infectious Diseases Society of America (IDWeek) 2021 – VIRTUAL**

**Virologic Failure Among Treatment-Experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) VS 3-Drug (3DR) Regimens**

**Authors:** Paul E. Sax, Joseph J. Eron, Janna Radtchenko, Helena Diaz-Cuervo, Mark Moore, Steven Santiago, Moti Ramgopal, Karam Mounzer, and Richard A. Elion

[ID Week Virtual; 2021 September 29- October 3](#)

Oral presented at: IDWeek 2021 VIRTUAL. 2021 September 29- October 3; Published in IDWeek site




The American Conference For The Treatment Of HIV (ACTHIV) 2021 – VIRTUAL

**Variables Associated with Lack of Suppression on Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH) in the US**

**Authors:** Richard A Elion, MD, Joe J Eron, MD, Julie Priest, MSPH, Janna Radtchenko, MBA, Moti Rampogal, MD, Alan Oglesby, MPH, and M Keith Rawlings, MD

[ACTHIV Presentations Database](#)

ePoster presented at: Virtual ACTHIV 2021 Conference. 2021 May 20-22. Abstract was also published in The NMA Journal- 112 (5 Supplement) (pp S25), October 2020




International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 – VIRTUAL

**Understanding Real-World Utilization of Pre-Exposure Prophylaxis (PrEP): Data from Trio Health HIV Research Network**

**Authors:** Janna Radtchenko, MBA, and Rick Elion, MD  
DOI: [10.1016/j.jval.2021.04.1268](https://doi.org/10.1016/j.jval.2021.04.1268)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20. Published in Value in Health and ISPOR site




Conference on Retroviruses and Opportunistic Infections (CROI) 2021- VIRTUAL

**Weight Gain After Switching Different Integrase Strand Transfer Inhibitors (INSTI)**

**Authors:** Grace A. McComsey, MD, Paul E. Sax, Keri N. Althoff, Janna Radtchenko, Helena Diaz-Cuervo, Joshua Gruber, Moti Ramgopal, Steven Santiago, Graeme Moyle, Karam Mounzer, and Richard A. Elion  
[CROI 2021 Abstract eBook: Page 190-#503](#)

Oral presented at: VIRTUAL CROI 2021. Annual Conference on Retroviruses and Opportunistic Infections; 2021 Mar 6-10



Infectious Diseases Society of America (IDWeek) 2020 – VIRTUAL

**Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH)**

**Authors:** M Keith Rawlings, MD Additional **Authors:** Joe J Eron, MD, Julie Priest, MSPH, Janna Radtchenko, MBA, Joe Mrus, MD, Moti Ramgopal, MD, Alan Oglesby, MPH, Faith Fletcher, PhD, and Richard A Elion, MD  
[ID Week Virtual; 2020 October 21-25: 1704](#)

Poster presented at: IDWeek 2020 VIRTUAL. 2020 October 21-25;  
 Published in Open Forum Infectious Diseases and IDWeek site



**Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)**

**Authors:** Grace A. McComsey, Paul E. Sax, Keri N. Althoff, Todd T. Brown, Janna Radtchenko, Helena Diaz-Cuervo, Moti Ramgopal, Steven Santiago, Graeme Moyle, Karam Mounzer, and Richard A. Elion  
[ID Week Virtual; 2020 October 21-25: LB-7](#)

Oral presented at: IDWeek 2020 VIRTUAL. 2020 October 21-25; Published in Open Forum Infectious Diseases and IDWeek site



**HIV Glasgow 2020 - VIRTUAL**

**Impact of Adherence on Viral Suppression with Bictegravir and Dolutegravir (DTG)- Containing Triple Therapy in Clinical Practice**

**Authors:** Paul E. Sax, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Helena Diaz-Cuervo, Karam Mounzer, Moti Ramgopal, Steven Santiago, and Richard A. Elion  
[DOI: 10.1002/jia.2.25616: P029](#)

Poster presented at: HIV Glasgow VIRTUAL. 2020 October 5-8; Published in Journal of the International AIDS Society and Glasgow site



**International AIDS Conference (IAS) 2020 – VIRTUAL**

**Characteristics of Patients Living With HIV (PLWH) and HIV Treatment Outcomes in Community Practices in Southern Vs Non-Southern US Regions**

**Authors:** Keith Rawlings, MD, Paul Sax, MD, Julie Priest MSPH, Janna Radtchenko, MBA, Joe Mrus, MD, Joe Eron, MD, Alan Oglesby, MPH, Keri Althoff, PhD, Faith Fletcher, PhD, Moti Ramgopal, MD, Steven Santiago, MD, Richard A Elion, MD  
[23<sup>rd</sup> International AIDS Conference Virtual; 2020 July 6-10: PEB0354](#)

Poster presented at: VIRTUAL 23<sup>rd</sup> International AIDS Conference; 2020 July 6-10



**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020- VIRTUAL**

**Patterns of Adherence in Bictegravir and Dolutegravir-Based Regimens**

**Authors:** Paul E. Sax, Joseph J. Eron, Andrew Frick, Scott Milligan, Moti Ramgopal, Steven Santiago, Richard A. Elion

[Value in Health, Volume 23, Supplement 1, S168, May 01, 2020](#)

Poster presented at: VIRTUAL ISPOR 2020 May 18-20; Published in Value in Health and ISPOR site




**Conference on Retroviruses and Opportunistic Infections (CROI) 2020- VIRTUAL**

**Patterns of Adherence in Bictegravir and Dolutegravir-Based Regimens**

**Authors:** Paul E. Sax, Joseph J. Eron, Andrew Frick, Scott Milligan, Moti Ramgopal, Steven Santiago, and Richard A. Elion

[The Conference on Retroviruses and Opportunistic Infections \(CROI\) Virtual; 2020 Mar 8-11: 495](#)

Poster presented at: VIRTUAL CROI 2020. Annual Conference on Retroviruses and Opportunistic Infections; 2020 Mar 8-11



**Do Prescribing Data Reflect Actual Treatment in People With HIV?**

**Authors:** Joseph J. Eron, Dushyantha Jayaweera, Gregory D. Huhn, Kelsey Milligan, Scott Milligan, Paul E. Sax, Keith Spitz, and Richard A. Elion

[The Conference on Retroviruses and Opportunistic Infections \(CROI\) Virtual; 2020 Mar 8-11: 499](#)

Poster presented at: VIRTUAL CROI 2020. Annual Conference on Retroviruses and Opportunistic Infections; 2020 Mar 8-11




**Understanding Who Does and Does Not Gain Weight With Integrase Inhibitors (INSTI)**

**Authors:** Grace A. McComsey, Keri N. Althoff, Todd T. Brown, Joseph J. Eron, Gregory D. Huhn, Anthony Mills, Graeme Moyle, Soodi Navadeh, Janna Radtchenko, Paul E. Sax, and Richard A. Elion

[The Conference on Retroviruses and Opportunistic Infections \(CROI\) Virtual; 2020 Mar 8-11: 676](#)

Poster presented at: VIRTUAL CROI 2020. Annual Conference on Retroviruses and Opportunistic Infections; 2020 Mar 8-11



**Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV/HCV**

**Authors:** Sonia Vibhakar Patel, Dushyantha T. Jayaweera†, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax, Jason Gillman, Karam Mounzer, Richard A. Elion, and Gregory D. Huhn DOI: [10.1371/journal.pone.0228847](https://doi.org/10.1371/journal.pone.0228847)

Published in: PLOS ONE: February 13, 2020



**The European AIDS Clinical Society (EACS) 2019**

**Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies**

**Authors:** R. Elion, K. Althoff, J. Eron, J. Gillman, R. Haubrich, G. Huhn, S. Milligan, A. Mills, K. Mounzer, G. Moyle, J. Radtchenko, S. Santiago, P. Sax, and D. Jayaweera

[The 17<sup>th</sup> European AIDS Clinical Society; 2019 Nov 6-9; Basel, Switzerland: PE19](#)

Poster presented at: The 17<sup>th</sup> European AIDS Conference; 2019 Nov 6-9; Basel, Switzerland



**The European Association for the Study of the Liver (EASL) 2019**

**Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US**

**Authors:** Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer, and Rick Elion  
[Online Access](#)

Poster presented at: The International Liver Congress. 54<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



**Conference on Retroviruses and Opportunistic Infections (CROI) 2019**

**Weight Gain During Treatment Among 3,468 Treatment-Experienced Adults with HIV**

**Authors:** Grace A McComsey, Joseph J Eron, Steven Santiago, Karam Mounzer, Graeme Moyle, Thanes Vanig, Paul E Sax, Keri N Althoff, Scott Milligan, Richard, Haubrich, and Richard A Elion.  
[The Conference on Retroviruses and Opportunistic Infections \(CROI\) Virtual: 2019 Mar 4-7: 671](#)

Poster presented at: CROI 2019. Annual Conference on Retroviruses and Opportunistic Infections; 2019 Mar 4-7; Seattle, WA



HIV Glasgow 2018

**Clinical Observations of Antiretroviral (ART) Switching in HIV- suppressed Patients After Availability of TAF**

**Authors:** Richard Elion, Joseph Eron, Steven Santiago, Paul Sax, Moti Ramgopal, Greg Huhn, Scott Milligan, Keri Althoff, and Jonathan Winston  
**DOI:** [10.1002/jia.2.25187](https://doi.org/10.1002/jia.2.25187): P114

Poster presented at: HIV Glasgow. 2018 October 28-31; Glasgow, UK;  
 Published in Journal of the International AIDS Society and Glasgow site



Digestive Disease Week (DDW) 2018

**Behavioral and Clinical Factors and Direct Acting Antiviral (DAA) Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network**

**Authors:** Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, and Karam Mounzer  
**DOI:** [10.1016/S0016-5085\(18\)33670-9](https://doi.org/10.1016/S0016-5085(18)33670-9)

Oral presented at: Digestive Disease Week. 2018 June 2-5; Washington, DC


Behavioral and Clinical Factors and Direct Acting Antiviral (DAA) Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network



**Untreated HCV in HIV/HCV Co-Infection Data from the TRIO Network**

**Authors:** Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion  
**DOI:** [10.1016/S0016-5085\(18\)33931-3](https://doi.org/10.1016/S0016-5085(18)33931-3)

Poster presented at: Digestive Disease Week. 2018 June 2-5; Washington DC




The European Association for the Study of the Liver (EASL) 2018

**Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network**

**Authors:** Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion  
**DOI:** [10.1016/S0168-8278\(18\)30723-2](https://doi.org/10.1016/S0168-8278(18)30723-2)


Poster presented at: The International Liver Congress. 53<sup>rd</sup> Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France



**Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network**

**Authors:** Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion  
 DOI: [10.1016/S0168-8278\(18\)30735-9](https://doi.org/10.1016/S0168-8278(18)30735-9)

Poster presented at: The International Liver Congress. 53<sup>rd</sup> Annual Meeting of the European Association for the Study of the Liver; 2018 Apr 11-15; Paris, France




**HAE**

**American Academy of Allergy, Asthma, & Immunology/ World Allergy Organizations (AAAAI/WAO) Joint Congress 2025**

**Long-Term Prophylaxis for Hereditary Angioedema: Real-World Treatment Patterns in Selected US Allergy Clinics**

**Authors:** Huamin Henry Li, Jason Raasch, Marc Riedi, Scott Milligan, Jim Ruggles, Cathy Schnabel, Kathleen F. Villa, Monica McClain


Poster presented at: AAAAI/WAO; 2025 February 28-March 3; San Diego, CA  
 DOI: [10.1016/j.jaci.2024.12.744](https://doi.org/10.1016/j.jaci.2024.12.744)



**Study to Adjudicate Hereditary Angioedema with Normal C1INH Diagnoses in the PIONEER-HAE Database**

**Authors:** Maeve O'Connor, Dana Winthrow, Scott Milligan, Vibha Desai, Paul K. Audhya, Marc A. Riedi

Poster presented at: AAAAI/WAO; 2025 February 28-March 3; San Diego, CA  
 DOI: [10.1016/j.jaci.2024.12.988](https://doi.org/10.1016/j.jaci.2024.12.988)



**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023**

**Barriers to Persisting on Prophylactic Treatment For C1-Esterase Inhibitor Deficient Hereditary Angioedema; Observations from Community Immunology**

**Authors:** Jason Raasch, William R. Lumry, Scott C. Milligan, and Marc Riedi  
 DOI: <https://doi.org/10.1016/j.jval.2023.03.2053>

Poster presented at: ISPOR 2023 Conference; 2023 May 7-10; Boston, MA.  
 Published in Value in Health and ISPOR site



**American College of Allergy, Asthma & Immunology (ACAAI) 2022**

**Attack Location And Severity/Resolution In Patients With Hereditary Angioedema (HAE); Observations From Community Immunology**

**Authors:** William R. Lumry, H. Henry Li, Scott C. Milligan, Jason Raasch, and Marc Riedl  
 DOI: [10.1016/j.anaai.2022.08.593](https://doi.org/10.1016/j.anaai.2022.08.593)


Poster presented at: American College of Allergy, Asthma & Immunology-2022 Annual Scientific Meeting, 2022 Nov 10-14; Louisville, Kentucky



**Development Of The Patient-Important Outcomes National Data Repository (PIONEER) For Hereditary Angioedema (HAE)**

**Authors:** William R. Lumry, Joshua Jacobs, H. Henry Li, Scott C. Milligan, Maeve E. O'Connor, Jason Raasch, and Marc Riedl  
 DOI: [10.1016/j.anaai.2022.08.591](https://doi.org/10.1016/j.anaai.2022.08.591)

Poster presented at: American College of Allergy, Asthma & Immunology-2022 Annual Scientific Meeting, 2022 Nov 10-14; Louisville, Kentucky



**IPF/PAH**

**Pulmonary Circulation Journal 2023**

**Characteristics of Patients with Pulmonary Arterial Hypertension from an Innovative, Comprehensive Real-World Patient Data Repository**

**Authors:** Harrison W. Farber, Murali M. Chakinala, Michelle Cho, Robert P. Frantz, Andrew Frick, Lisa Lancaster, Scott Milligan, Ronald Oudiz, Sumeet Panjabi, Yuen Tsang, Steven D. Nathan

*Pulmonary Circulation* 13 (3): e12258. July 06, 2023  
<https://doi.org/10.1002/pul2.12258>.



**American Thoracic Society (ATS) 2022**

**Development of a Comprehensive, Integrated Patient Data Repository of US Pulmonary Hypertension (PH) Patients to Assess the Impact of Clinical Care on Patient Outcomes**

**Authors:** H.W. Farber, S. Milligan, S. Panjabi, Y. Tsang, K. Bettencourt, and M. Cho  
 DOI: [10.1164/ajrccm-conference.2022.205.1.MeetingAbstracts.A3997](https://doi.org/10.1164/ajrccm-conference.2022.205.1.MeetingAbstracts.A3997)

Poster presented at: ATS 2022 May 13-18



CHEST Annual Meeting 2021 – VIRTUAL

**Comparison of Idiopathic Versus Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (PAH) Groups in US Clinical Practice**

**Authors:** Ronald J. Oudiz, MD, FCCP, Murali M. Chakinala, MD, FCCP, Robert P. Frantz, MD, Adaani E. Frost, MD, Lisa H. Lancaster, MD, FCCP, Steven D. Nathan, MBBCh, FCCP, Sumeet Panjabi, PhD, Andrew Frick, MS, and Harrison W. Farber, MD

[DOI: 10.1016/j.chest.2021.07.2006](https://doi.org/10.1016/j.chest.2021.07.2006)

ePoster presented at: Virtual CHEST 2021 Conference. 2021 October 17-20.



**Transthoracic Echocardiogram (ECHO) and Right Heart Catheterization (RHC) as Disease Management Tools for Patients with PAH in US Clinical Practice**

**Authors:** Murali M. Chakinala, MD, FCCP, Robert P. Frantz, MD, Lisa H. Lancaster, MD, FCCP, Steven D. Nathan, MBBCh, FCCP, Ronald J. Oudiz, MD, FCCP, Sumeet Panjabi, PhD, Nicole Wick, and Harrison W. Farber, MD

[DOI: 10.1016/j.chest.2021.07.2023](https://doi.org/10.1016/j.chest.2021.07.2023)

ePoster presented at: Virtual CHEST 2021 Conference. 2021 October 17-20.



**Care and Characteristics of Patients with Pulmonary Arterial Hypertension (PAH) in US Clinical Practice**

**Authors:** Adaani E. Frost, MD, Murali M. Chakinala, MD, FCCP, Robert P. Frantz, MD, Lisa H. Lancaster, MD, FCCP, Steven D. Nathan, MBBCh, FCCP, Ronald J. Oudiz, MD, FCCP, Sumeet Panjabi, PhD, Scott Milligan, PhD, and Harrison W. Farber, MD

[DOI: 10.1016/j.chest.2021.07.1999](https://doi.org/10.1016/j.chest.2021.07.1999)

ePoster presented at: Virtual CHEST 2021 Conference. 2021 October 17-20.



International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 – VIRTUAL

**Comorbid Burden and Survival Risk Metrics of Pulmonary Hypertension (PH) Patients in US-Clinical Care: Real-World Assessments from the TRIO Health PH Registry**

**Authors:** Murali Chakinala, Deepali Rane, Ronald Oudiz, Adaani Frost, Robert Frantz, Steven Nathan, and Harrison Farber

[ISPOR Presentations Database](#)

[DOI: 10.1016/j.jval.2021.04.344](https://doi.org/10.1016/j.jval.2021.04.344)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20. Published in Value in Health and ISPOR site



**Real-World Clinical Characteristics of 112 Patients with Interstitial Lung Disease (ILD); Update from the Trio Health ILD Registry**

**Authors:** Frantz RP, Rane D, Nathan SD, Lancaster L, Frost AE, Chakinala MM, Oudiz RJ, and Farber HW

[ISPOR Presentations Database](#)  
DOI: [10.1016/j.jval.2021.04.1099](https://doi.org/10.1016/j.jval.2021.04.1099)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.  
Published in Value in Health and ISPOR site



**American Thoracic Society (ATS) 2021 VIRTUAL**

**Comorbid Burden and Survival Risk Metrics of Pulmonary Hypertension (PH) Patients in US-Clinical Care: Real-World Assessments from the TRIO Health PH Registry**

**Authors:** Murali Chakinala, Deepali Rane, Ronald Oudiz, Adaani Frost, Robert Frantz, Steven Nathan, and Harrison Farber

DOI: [10.1164/ajrccm-conference.2021.203.1.MeetingAbstracts.A1594](https://doi.org/10.1164/ajrccm-conference.2021.203.1.MeetingAbstracts.A1594)  
American Journal of Respiratory and Critical Care Medicine 2021; 203:A1594

ePoster presented at: ATS 2021 May 14-19



**American Thoracic Society (ATS) 2020**

**A Platform to Combine Clinical, Prescription, And Dispensing Data to Better Inform Idiopathic Pulmonary Fibrosis Care; The Trio Registry**

**Authors:** Steven Nathan, MD, Murali Chakinala, MD, Robert Frantz, MD, Adaani Frost, MD, Lisa Lancaster, MD, Kelsey Milligan, Scott Milligan, PhD, Ronald Oudiz, MD, and Harrison Farber, MD

DOI: [10.1164/ajrccm-conference.2020.201.1.MeetingAbstracts.A1519](https://doi.org/10.1164/ajrccm-conference.2020.201.1.MeetingAbstracts.A1519)  
American Journal of Respiratory and Critical Care Medicine 2020; 201:A1519

Poster presented at: ATS 2020 May 15-20; Philadelphia, PA (Cancelled)



**The Trio Pulmonary Arterial Hypertension Registry; A Platform Combining EMR Clinical Measures with Pharmacy Prescription and Dispensing Data**

**Authors:** Steven Nathan, MD, Harrison Farber, MD, Murali Chakinala, MD, Robert Frantz, MD, Adaani Frost, MD, Scott Milligan, PhD, and Ronald Oudiz, MD

DOI: [10.1164/ajrccm-conference.2020.201.1.MeetingAbstracts.A6593](https://doi.org/10.1164/ajrccm-conference.2020.201.1.MeetingAbstracts.A6593)  
American Journal of Respiratory and Critical Care Medicine 2020; 201:A6593

Poster presented at: ATS 2020 May 15-20; Philadelphia, PA (Cancelled)



NASH

**The Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease**

**Authors:** Joana Vieira Barbosa, MD, MSc, Scott Milligan, PhD, Andrew Frick, MSc, Jeremy Broestl, BSc, Zobair Younossi, MD, MPH, Nezam H. Afdhal, MD, and Michelle Lai, MD, MPH  
 DOI: [10.14309/ajg.000000000001606](https://doi.org/10.14309/ajg.000000000001606)

Published in: The American Journal of GASTROENTEROLOGY: Online January 18, 2022



**The American Association for the Study of Liver Diseases (AASLD) 2021 VIRTUAL**

**The Impact of Race on NAFLD Outcomes in US Clinical Practice**

**Authors:** Scott B. Minchenberg, Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Nezam H. Afdhal, and Michelle Lai  
 DOI: [10.1002/hep.32188:1747](https://doi.org/10.1002/hep.32188:1747)

Poster presented at: The Liver Meeting. 72nd Annual Meeting of the American Association for the Study of Liver Diseases; 2021 Nov 12-15 VIRTUAL



**Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD**

**Authors:** Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Jeremy Broestl, Zobair Younossi, Nezam H. Afdhal, and Michelle Lai  
 DOI: [10.1002/hep4.1841](https://doi.org/10.1002/hep4.1841)

Published in: Hepatology Communications: Online December 30, 2021




**The American Association for the Study of Liver Diseases (AASLD) 2021 VIRTUAL**

**The Impact of Race on NAFLD Outcomes in US Clinical Practice**

**Authors:** Scott B. Minchenberg, Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Nezam H. Afdhal, and Michelle Lai  
 DOI: [10.1002/hep.32188:1747](https://doi.org/10.1002/hep.32188:1747)

Poster presented at: The Liver Meeting. 72nd Annual Meeting of the American Association for the Study of Liver Diseases; 2021 Nov 12-15 VIRTUAL



**Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD**

**Authors:** Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Jeremy Broestl, Zobair Younossi, Nezam H. Afdhal, and Michelle Lai  
 DOI: [10.1002/hep4.1841](https://doi.org/10.1002/hep4.1841)

Published in: Hepatology Communications: Online December 30, 2021



**The European Association for the Study of the Liver (EASL) 2020 – VIRTUAL**

**Association of FIB4 Score with Major Cardiovascular Events (MACE) in Real-World Populations Diagnosed with NASH or NAFLD in US Clinical Practice**

**Authors:** Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal  
[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #THU037](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29



**Association of FIB4 Score with Disease Progression in Real-World Populations Diagnosed with NAFLD/NASH or at Risk of NASH in US Clinical Practice**

**Authors:** Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal  
[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #THU036](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29



**Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice**

**Authors:** Michelle Lai, Jeremy Broestl, Kavita Juneja, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal  
[Journal of Hepatology. August 2020; 73 \(suppl 1\): Abstract #FRI107](#)

Poster presented at: The Digital International Liver Congress 2020; 2020 Aug 27-29



**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020- VIRTUAL**

**Evaluation of Liver Outcomes Relative to Use of GLP-1 Receptor Agonists (GLP1A) and/or SGLT-2 Inhibitors (SGLT2I) in Real-World Populations Diagnosed with Type II Diabetes (T2DM) and NASH/NAFLD or at Risk of Nash**

**Authors:** Michelle Lai, Andrew Frick, Kavita Juneja, Bruce Koch, Scott Milligan, Macky Natha, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

[DOI: 10.1016/j.jval.2020.04.365](https://doi.org/10.1016/j.jval.2020.04.365)

Poster presented at: Virtual ISPOR 2020 Conference. 2020 May 15-20; Published in Value in Health and ISPOR site



**Lean and Obese Patients with Non-Alcoholic Steatohepatitis (NASH) / Non-Alcoholic Fatty Liver Disease (NAFLD); Comparisons of Populations and Disease Progression**

**Authors:** Michelle Lai, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

[DOI: 10.1016/j.jval.2020.04.363](https://doi.org/10.1016/j.jval.2020.04.363)

Poster presented at: Virtual ISPOR 2020 Conference. 2020 May 15-20; Published in Value in Health and ISPOR site



**Digestive Disease Week (DDW) 2020**

**Association of FIB4 Score with Major Cardiovascular Events (MACE) in Real-World Populations Diagnosed with NASH or NAFLD in US Clinical Practice**

**Authors:** Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

[DOI: 10.1016/S0016-5085\(20\)33833-6](https://doi.org/10.1016/S0016-5085(20)33833-6)

Oral presented online at: Digestive Disease Week. 2020 May 2-5; Chicago, IL (Cancelled)

Association of FIB-4 score with Major Cardiovascular Events (MACE) in real-world populations diagnosed with NASH or NAFLD in US Clinical Practice

Michelle Lai<sup>1</sup>, Jeremy Broestl<sup>2</sup>, Andrew Frick<sup>3</sup>, Richard Haubrich<sup>4</sup>, Bruce Koch<sup>5</sup>, Scott Milligan<sup>6</sup>, Macky Natha<sup>7</sup>, Zobair Younossi<sup>8</sup>, and Nezam Afdhal<sup>9</sup>  
<sup>1</sup>Health System Enterprise, LLC, <sup>2</sup>TruHealth Analytics, <sup>3</sup>TruHealth Services, Inc., <sup>4</sup>Center for Liver Diseases, <sup>5</sup>Department of Medicine, <sup>6</sup>Massachusetts General Hospital, <sup>7</sup>Fred Hutchinson Cancer Research Center, <sup>8</sup>Center for Integrated Health, <sup>9</sup>West Virginia Health System, Parkersburg, WV

**Association of FIB4 Score with Disease Progression in Real-World Populations Diagnosed with NAFLD/NASH or at Risk of NASH in US Clinical Practice**

**Authors:** Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

[DOI: 10.1016/S0016-5085\(20\)34210-4](https://doi.org/10.1016/S0016-5085(20)34210-4)

Poster presented at: Digestive Disease Week. 2020 May 2-5; Chicago, IL (Cancelled)



**Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice**

**Authors:** Michelle Lai, Jeremy Broestl, Kavita Juneja, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

[DOI: 10.1016/S0016-5085\(20\)34283-9](https://doi.org/10.1016/S0016-5085(20)34283-9)

Poster presented at: Digestive Disease Week. 2020 May 2-5; Chicago, IL (Cancelled)




Digestive Disease Week (DDW) 2019

Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Authors: Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Oral presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria




The European Association for the Study of the Liver (EASL) 2019

Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Authors: Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal.

Poster presented at: The International Liver Congress. 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria



RHEUMATOLOGY

Journal Manuscripts - Lupus Science & Medicine

Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data

Authors: Karen Worley, Scott Milligan, Bernard Rubin

DOI: [10.1136/lupus-2023-001024](https://doi.org/10.1136/lupus-2023-001024)

Journal published in Lupus Science & Medicine 2023 Dec 22;10:e001024. doi:10.1136/lupus-2023-001024



American College of Rheumatology (ACR) Convergence 2023

**Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab – Observations from the American Rheumatology Network (ARN) in the U.S.**

**Authors:** Vasileios Kyttaris, Gelareh Atefi, Dan Persons, Chris Ambrose, Scott Milligan, Sandra Sze-jung Wu


Poster presented at: ACR Convergence 2023, November 10-15; San Diego, California



**The Effect of Belimumab on Steroid Use in Patients With SLE: Results From a Retrospective Observational Study of Real-World Data From a US Rheumatology Provider Network**

**Authors:** Karen Worley, Scott Milligan, Bernard Rubin

Poster presented at: ACR Convergence 2023, November 10-15; San Diego, California



**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023**

**Reuse of Tumor Necrosis Factor Inhibitors for Treatment of Rheumatoid Arthritis despite Discordance with Patient Important Outcomes and Standard Disease Assessments**

**Authors:** Frick A, Broestl J, Cox K, Milligan K, Persons D, Milligan S  
DOI: <https://doi.org/10.1016/j.jval.2023.03.092>

Poster presented at: ISPOR 2023 Conference; 2023 May 7-10; Boston, MA. Published in Value in Health and ISPOR site



**Towards Better Rheumatoid Arthritis Management by Identification of Potentially Manageable Conditions Observed with Early Discontinuation of Biologic/Targeted Synthetic (b/ts) DMARDs**

**Authors:** Christopher Adams, Simon Helfgott, Kent Huston, Andrew Frick, Scott Milligan, Jasvinder A. Singh, Nehad Soloman, Colin C. Edgerton  
DOI: <https://doi.org/10.1016/j.jval.2023.03.136>

Poster presented at: ISPOR 2023 Conference; 2023 May 7-10; Boston, MA. Published in Value in Health and ISPOR site



**Are Biosimilars Equivalent To Originator Molecules In The Real-World? Assessments Of Efficacy, Toxicity, And Tolerability of Infliximabs in Infliximab-Naïve Patients With Rheumatoid Arthritis**

**Authors:** Jasvinder A. Singh, Simon Helfgott, Kent Kwas Huston, Nehad Soloman, Andrew Frick, Scott Milligan, Colin Edgerton  
DOI: <https://doi.org/10.1016/j.jval.2023.03.227>

Poster presented at: ISPOR 2023 Conference; 2023 May 7-10; Boston, MA. Published in Value in Health and ISPOR site



**Persistence on Conventional Synthetic DMARDS without Evidence of Rheumatoid Arthritis Control; Identifying Populations That May Benefit from Availability of Lower-Cost TNFi Biosimilars**

**Authors:** Frick A, Broestl J, Cox K, Milligan K, Persons D, Milligan S  
 DOI: <https://doi.org/10.1016/j.jval.2023.03.2336>

Poster presented at: ISPOR 2023 Conference; 2023 May 7-10; Boston, MA.  
 Published in Value in Health and ISPOR site



**American College of Rheumatology (ACR) Convergence 2022**

**Reasons For Early Discontinuation Of Targeted Synthetic (ts) Or Biologic (b) DMARDS; Chart Review of 20,343 Drug Episodes Given To Patients With Rheumatoid Arthritis**

**Authors:** Kent Kwas Huston, Christopher Adams, Simon Helfgott, Jasvinder A. Singh, Nehad Soloman, Dan Persons, Scott Milligan, and Colin Edgerton  
[ACR Convergence 2022: Abstract Number: 0264](#)


Poster presented at: ACR Convergence 2022; 2022 Nov 10-14; Philadelphia, Pennsylvania



**Review of 167,990 Same day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation**

**Authors:** Simon Helfgott, Kent Kwas Huston, Jasvinder A. Singh, Nehad Soloman, Andrew Frick, Scott Milligan, and Colin Edgerton  
[ACR Convergence 2022: Abstract Number: 0927](#)

Poster presented at: ACR Convergence 2022; 2022 Nov 10-14; Philadelphia, Pennsylvania



**Development of the Patient-Important Outcomes National Data Repository (PIONEER) for Rheumatic Diseases; an Enhanced Database combining Electronic Medical Data with Insight from Chart Reviews**

**Authors:** Simon Helfgott, Kent Kwas Huston, Jasvinder A. Singh, Nehad Soloman, Jeremy Broestl, Kimmi Cox, Kelsey Milligan, and Colin Edgerton  
[ACR Convergence 2022: Abstract Number: 1954](#)

Poster presented at: ACR Convergence 2022; 2022 Nov 10-14; Philadelphia, Pennsylvania



**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 – VIRTUAL**

**Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)**

**Authors:** Colin Edgerton, Andrew Frick, Simon Helfgott, Ken Kwas Huston, Jasvinder Singh, and Nehad Soloman  
 DOI: [10.1016/j.jval.2021.04.1152](https://doi.org/10.1016/j.jval.2021.04.1152)


ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.  
 Published in Value in Health and ISPOR site



**Disparities in Targeted Immune Modulating (TIM) Treatment for Elderly Compared to Younger Patients with Psoriatic Arthritis (PSA)**

**Authors:** Jasvinder Singh, Andrew Frick, Simon Helfgott, Kent Kwas Huston, Nehad Soloman, John Tesser, and Colin Edgerton  
 DOI: [10.1016/j.jval.2021.04.1154](https://doi.org/10.1016/j.jval.2021.04.1154)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.  
 Published in Value in Health and ISPOR site



**Outcomes with Infliximab and Its Biosimilars in Patients with Rheumatoid Arthritis (RA): Real-World Experience in the US**

**Authors:** Simon Helfgott, MD, Janna Radtchenko, MBA, Nehad Soloman, MD, Kent Kwas Huston, MD, Jasvinder Singh, MD, MPH, and Colin Edgerton, MD  
[ISPOR Presentations Database](https://www.ispor.org/ISPOR-Presentations-Database)  
 DOI: [10.1016/j.jval.2021.04.075](https://doi.org/10.1016/j.jval.2021.04.075)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.  
 Published in Value in Health and ISPOR site



**Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network (ARN)**


**Authors:** Simon Helfgott, Deepali Rane, Kent Kwas Huston, Jeremy Broestl, Jasvinder Singh, Nehad Soloman, and Colin Edgerton  
[ISPOR Presentations Database](https://www.ispor.org/ISPOR-Presentations-Database)

ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.  
 Published in Value in Health and ISPOR site



**Real-World Utilization of Janus Kinase Inhibitors (JAKs) and Biologics in Patients with Rheumatoid Arthritis (RA)**


**Authors:** Jasvinder A. Singh, MD, MPH, Janna Radtchenko, MBA, Nehad Soloman, MD, Kwas Huston, MD, Simon M. Helfgott, MD, and Colin C. Edgerton, MD  
[ISPOR Presentations Database](https://www.ispor.org/ISPOR-Presentations-Database)  
 DOI: [10.1016/j.jval.2021.04.678](https://doi.org/10.1016/j.jval.2021.04.678)



ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.  
Published in Value in Health and ISPOR site

**Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)**

**Authors:** Nehad Soloman, Mona Amin, Kimmi Cox, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton  
[ISPOR Presentations Database](#)  
DOI: [10.1016/j.jval.2021.04.681](https://doi.org/10.1016/j.jval.2021.04.681)



ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.  
Published in Value in Health and ISPOR site

**Management of Gout after Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)**

**Authors:** Nehad Soloman, Mona Amin, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Kelsey Milligan, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton  
[ISPOR Presentations Database](#)  
DOI: [10.1016/j.jval.2021.04.682](https://doi.org/10.1016/j.jval.2021.04.682)




ePoster presented at: Virtual ISPOR 2021 Conference. 2021 May 17-20.  
Published in Value in Health and ISPOR site

**Academy of Managed Care Pharmacy (AMCP) 2021 VIRTUAL**

**Real-World Utilization of Janus Kinase Inhibitors (JAKs) and Biologics in Patients with Rheumatoid Arthritis (RA)**

**Authors:** Janna Radtchenko, Jasvinder A. Singh, MD, MPH, Nehad Soloman, MD, Kwas Huston, MD, Simon M. Helfgott, MD, and Colin C. Edgerton, MD  
DOI: [10.18553/jmcp.2021.27.4-a.s1](https://doi.org/10.18553/jmcp.2021.27.4-a.s1)  
Journal of Managed Care + Specialty Pharmacy 2021 Apr; 27(4-a Suppl): S103-M9



ePoster presented at: AMCP Managed Care and Specialty Pharmacy Annual Meeting, 2021 Apr 12-16 and published in Journal of Managed Care + Specialty Pharmacy

**American College of Rheumatology (ACR) Convergence 2020 - VIRTUAL**

**Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US**

**Authors:** Simon Helfgott, Janna Radtchenko, Nehad Soloman, Kent Kwas Huston, Jasvinder Singh, and Colin Edgerton  
[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



**Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network**

**Authors:** Simon Helfgott, Jeremy Broestl, Kent Kwas Huston, Deepali Rane, Jasvinder Singh, Nehad Soloman, and Colin Edgerton  
[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



**Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)**

**Authors:** Nehad Soloman, Mona Amin, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Kelsey Milligan, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton  
[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)


Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



**Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)**

**Authors:** Nehad Soloman, Mona Amin, Kimmi Cox, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton  
[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



**Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)**

**Authors:** Colin Edgerton, Andrew Frick, Simon Helfgott, Kent Kwas Huston, Jasvinder Singh, and Nehad Soloman  
[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



**The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases**

**Authors:** Kent Kwas Huston, Simon Helfgott, Scott Milligan, Jasvinder Singh, Nehad Soloman, Brandon Weil, and Colin Edgerton

[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9




**Change in Utilization of Outpatient Services at US Community Rheumatology Practices During COVID-19 Outbreak**

**Authors:** Kent Kwas Huston, Nehad Soloman, Janna Radtchenko, Simon Helfgott, Jasvinder Singh, and Colin Edgerton

[Arthritis Rheumatol. 2020; 72 \(suppl 10\)](#)

Poster presented at: Virtual ACR Convergence 2020 Conference. 2020 Nov 5-9



**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020 – VIRTUAL**

**Outpatient Costs in Rheumatoid Arthritis (RA) Patients With VS Without Comorbidities**

**Authors:** Edgerton CC, Radtchenko J, and Holers VM

DOI: [10.1016/j.jval.2020.04.691](https://doi.org/10.1016/j.jval.2020.04.691)

*Value in Health.* 2020; 23 (suppl 1): S214

Poster presented at: Virtual ISPOR 2020 Conference. 2020 May 15-20



**American College of Rheumatology (ACR) 2019**

**Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices**

**Authors:** Colin C. Edgerton, Janna Radtchenko, and V. Michael Holers

[Arthritis Rheumatol. 2019; 71 \(suppl 10\): Abstract #1138](#)

Poster presented at: American College of Rheumatology/ The Association of Rheumatology Professionals (ACR/ARP) Annual Meeting. 2019 November 8-13; Atlanta, GA




**RARE DISEASES**

**American Academy of Allergy, Asthma, & Immunology/ World Allergy Organizations (AAAAI/WAO) Joint Congress 2025**

**The Activated Phosphoinositide 3-kinase Delta Syndrome Characterization and Clinical Outcomes Immunologic Registry (APDS-CHOIR): Early Insights in Immunologic Phenotyping**

**Authors:** Kelli W. Williams, Valeria Duran, Andrew Frick, Nicholas L. Hartog, Nicholas L. Rider, Brian Hartline

Presentation presented at AAAAI/WAO; 2025 February 28- March 3; San Diego, CA  
DOI: [10.1016/j.jaci.2024.12.564](https://doi.org/10.1016/j.jaci.2024.12.564)




**Clinical Immunology Society 2025**

**Demographic and Clinical Characteristics of People with Activated Phosphoinositide kinase Delta Syndrome (APDS) in the APDS-Characterization and Clinical Outcomes Immunologic Registry (APDS-CHOIR)**

**Authors:** Nicholas Hartog, Valeria Duran, Andrew Frick, Kelli Williams, Nicholas Rider, Jason Raasch, Ashley Reiland Saucedo, Brian Hartline

Poster presented at CIS; 2024 May 1-4; Minneapolis, MN



3-

**Clinical Immunology Society 2024**

**Development of the Activated Phosphoinositide 3-kinase Delta Syndrome Characterization and Clinical Outcomes Immunologic Registry (APDS-CHOIR)**

**Authors:** Nicholas Hartog, Andrew Frick, Valeria Duran, Kelli Williams, Brian Hartline

Poster presented at CIS; 2024 May 1-4; Minneapolis, MN




**National Organization for Rare Disorders (NORD) 2019**

**Misdiagnosis of Desmoid Tumors; Insight from the Desmoid Tumor Research Foundation (DTRF) Patient Registry**

**Authors:** Kelly Mercier, Lynn Hernandez, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, and Kelsey Milligan

Poster presented at: NORD Rare Summit. 2019 October 21-22; Washington DC



**Quality of Life in Pediatric Patients with SYNGAP1-Related Non-Syndromic Intellectual Disability (NSID); Data from the SYNGAP1 (MRD5) Patient Registry**

**Authors:** Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov S, Milligan K


Poster presented at: NORD Rare Summit. 2019 October 21-22; Washington DC



**The PKU Patient Registry: Understanding the Natural History of PKU**

**Authors:** Olaf Bodamer MD PhD, Harvey Levy MD, Eileen Blakely, Christine Brown, Hilary Feldman, Rhonda Connolly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Kelsey Milligan, and Janna Radtchenko

Poster presented at: NORD Rare Summit. 2019 October 21-22; Washington DC




**European Hematology Association (EHA) 2019**

**Quality of Life and Demographics of Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry**

**Authors:** Caroline Kruse, Alexandra Kruse, Nancy Potthast, Vanessa Boulanger, Allison Seebald, Suzanne Rossov and Kelsey Milligan.

DOI: [10.1097/01.HS9.0000567492.92876.8b](https://doi.org/10.1097/01.HS9.0000567492.92876.8b)

Poster presented at: EHA 2019. The 24th Congress of the European Hematology Association; 2019 June 13-16; Amsterdam, The Netherlands




**Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019**

**Quality of Life (QOL) and Tumor Location in Patients with Desmoid Tumors; Data From The Desmoid Tumor Research Foundation (DTRF) Natural History Study**

**Authors:** Kelly Mercier, Lynne Hernandez, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, and Kelsey Milligan

DOI: [10.1200/JCO.2019.37.15\\_suppl.e18291](https://doi.org/10.1200/JCO.2019.37.15_suppl.e18291) *Journal of Clinical Oncology* 37, no. 15 suppl

Poster presented at: ASCO 2019. The 55th Annual Meeting of the American Society of Clinical Oncology; 2019 May 31- June 4; Chicago, Illinois




**International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019**

**Understanding Disease and Burden in Syngap1-Related Non-Syndromic Intellectual Disability (NSID) Using a Patient Registry Database**

**Authors:** Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J

DOI: [10.1016/j.jval.2019.04.1689](https://doi.org/10.1016/j.jval.2019.04.1689)

Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA. Published in Value in Health and ISPOR site



**Understanding Real-World Treatment Patterns and Quality of Life in Patients with Pemphigus and Pemphigoid Using a Patient Registry Database**

**Authors:** Yale ML, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J.  
 DOI: [10.1016/j.jval.2019.04.1697](https://doi.org/10.1016/j.jval.2019.04.1697)


Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA. Published in Value in Health and ISPOR site



**The Use of Patient Registry to Better Inform Healthcare Decision Makers and Improve Clinical Outcomes for Patients with Phenylketonuria (PKU)**

**Authors:** Bodamer O, Levy H, Blakely E, Brown C, Feldman H, Connolly R, and Moseley K.  
 DOI: [10.1016/j.jval.2019.04.1701](https://doi.org/10.1016/j.jval.2019.04.1701)

Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA. Published in Value in Health and ISPOR site



**The Use of Patient Reported Registry Data to Improve Health Outcomes for Patients with Opsoclonus Myoclonus Syndrome (OMS)**

**Authors:** Michaelis M, Khoury-Dennis C, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J.  
 DOI: [10.1016/j.jval.2019.04.1698](https://doi.org/10.1016/j.jval.2019.04.1698)

Poster presented at: ISPOR 2019 Conference; 2019 May 18-22; New Orleans, LA. Published in Value in Health and ISPOR site



**National Institute of Health (NIH) 2019**

**Understanding Demographics and Diagnosis in Syngap1-related Non-Syndromic Intellectual Disability (NSID) Patients Using a Patient Registry Database**

**Authors:** Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov K and Milligan K.  
 The Power of Patients: Informing Our Understanding of Rare Diseases: Posters and Acknowledgements

Poster presented at: Rare Disease Day at NIH 2019; 2019 February 28; Bethesda, MD



**National Organization for Rare Disorders (NORD) 2018**

**The Opsoclonus Myoclonus Syndrome (OMS) Registry: A Vehicle to Better Understand the Natural History and Experience of OMS Patients**

**Authors:** Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



**Symptoms and Diagnosis of Opsoclonus Myoclonus Syndrome (OMS): Early Data from the OMS Registry**

**Authors:** Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



**Treatment Utilization by Patients with Opsoclonus Myoclonus Syndrome (OMS): Insights from the OMS Registry**

**Authors:** Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



**NORD RareCare® Assistance Programs: Helping the Rare Disease Community Access Diagnostics and Care**

**Authors:** Jill Pollander, Pamela Gavin, and Jeremy Broestl


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



**The Pemphigus-Pemphigoid Registry: Real-World Diagnostic and Treatment Patterns**

**Authors:** Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



**The Pemphigus-Pemphigoid Registry: First Report of Patient Quality of Life Measures**

**Authors:** Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



**The Pemphigus-Pemphigoid Registry: A Platform to Improve Understanding and Advance Care**

**Authors:** Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



**The PKU Patient Registry: A Step for Better Disease Awareness and Improved Patient Outcomes**

**Authors:** Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



**The PKU Patient Registry: Understanding Diagnosis and Medical History of Patients with PKU**

**Authors:** Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan and Janna Radtchenko


Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



**The PKU Patient Registry: Evaluating Treatment Paradigms of Patients with PKU**

**Authors:** Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko

Poster presented at: NORD Rare Summit. 2018 October 15-16; Washington DC



ARTICLES

**The Next Chapter for Real World Evidence: Validating Data with the Patient Voice**

Tandon, Ramita  
PharmaVoice (November/December 2020): Page 31



**Coverage Denials Eyed in Surging HCV Rx Nonstarts**

Shaw, Gina.  
Specialty Pharmacy Continuum 6 (Mar/Apr 2017): Cover,15

